

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
31 March 2005 (31.03.2005)

PCT

(10) International Publication Number
WO 2005/028473 A1

(51) International Patent Classification⁷: **C07D 413/10**,
413/14

BOYER, Frederick, Earl, Jr. [US/US]; Pfizer Global Research and Development, 301 Henrietta Street, Kalamazoo, MI 49001 (US).

(21) International Application Number:
PCT/IB2004/002983

(74) Agent: **FULLER, Grover, F., Jr.**; Pfizer Inc., P.O. Box 1027, St. Louis, MO 63006 (US).

(22) International Filing Date:
13 September 2004 (13.09.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/505,329 23 September 2003 (23.09.2003) US

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicant (for all designated States except US): **PHARMACIA & UPJOHN COMPANY** [US/US]; 301 Henrietta Street, Kalamazoo, MI 49001 (US).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **JOSYULA, Vara, Prasad, Venkata, Nagendra** [US/US]; Pfizer Global Research and Development, 301 Henrietta Street, Kalamazoo, MI 49001 (US). **GADWOOD, Robert, C.** [US/US]; Pfizer Global Research and Development, 301 Henrietta Street, Kalamazoo, MI 49001 (US). **THOMASCO, Lisa, Marie** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340 (US). **KIM, Ji-Young** [US/KR]; Pfizer Global Research and Development, 301 Henrietta Street, Kalamazoo, MI 49001 (US). **CHOY, Allison, Laura** [US/US]; Pfizer Global Research and Development, 301 Henrietta Street, Kalamazoo, MI 49001 (US).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2005/028473 A1

(54) Title: ACYLOXYMETHYL CARBAMATE PRODRUGS OF OXAZOLIDINONES


(57) Abstract: The present invention relates to acyloxymethyl carbamate oxazolidinones. The compounds of the present invention have potent activity with excellent oral bioavailability against Gram-positive and Gram-negative bacteria.

FIELD OF INVENTION

BACKGROUND OF THE INVENTION

Among newer antibacterial agents, oxazolidinone compounds are the most recent synthetic class of antimicrobials active against a number of pathogenic microorganisms. However, some of these oxazolidinones are not absorbed sufficiently to achieve the desired blood levels in a mammalian subject. This invention provides a new type of oxazolidinone prodrug which remarkably enhances oral bioavailability of the compounds described herein. Prodrugs of the present invention are prepared by modifying functional groups present in a compound described herein in such a way that the modifications may be cleaved *in vivo* to release the parent compound.

The present invention provides a compound of formula I



I

or a pharmaceutically acceptable salt thereof wherein:

X is -SO-, -SO₂-, or -SONR⁶-;

Z is -C-, -CH-, or -N-;

each "....." is independently absent, or a bond;

each W is independently -CHR⁶-, -CHR⁶CH₂-, or absent;

R¹ is

- 5 (a) -NH₂,
 (b) -NHC₁₋₄alkyl,
 (c) -C₁₋₆alkyl, optionally substituted with 1-3 halo,
 (d) -C₂₋₆alkenyl,
 (e) -(CH₂)_nC(=O)C₁₋₄alkyl,
 10 (f) -OC₁₋₄alkyl,
 (g) -SC₁₋₄alkyl, or
 (h) -(CH₂)_nC₃₋₇cycloalkyl;

R² and R³ are independently -H, or -F;

R⁴ is -H, -C₁₋₄alkyl, or -CO₂R⁶;

15 R⁵ is

- (a) -C₁₋₁₀alkyl,
 (b) -C₃₋₇cycloalkyl,
 (c) -aryl,
 (d) -het,
 20 (e) -OC₁₋₁₀alkyl,
 (f) -O-C₃₋₇cycloalkyl,
 (g) -O-aryl,
 (h) -O-het,
 (i) -C(R⁶)(R⁷)NH₂,
 25 (j) -C(R⁶)(R⁷)NHCO₂C₁₋₄alkyl,
 (k) -C(R⁶)(R⁷)NHCOC(R⁶)(R⁷)NH₂, or
 (l) -C(R⁶)(R⁷)NHCOC(R⁶)(R⁷)NHCO₂C₁₋₄alkyl;

each R⁶ is independently -H, or -C₁₋₄alkyl;

each R⁷ is independently -H, -C₁₋₄alkyl wherein -C₁₋₄alkyl is optionally substituted
 30 with OR⁶, SR⁶, CO₂R⁶, CONH₂, NH₂, NHC(=NH)NH₂, phenyl, het, or R⁶ and R⁷
 taken together form het;

aryl is phenyl, biphenyl, or naphthyl;

het is an aromatic ring, or a saturated or unsaturated ring that is not aromatic, of 3 to 10 carbon atoms and 1 to 4 heteroatoms selected from the group consisting of O, NQ, and S within the ring, wherein Q is absent, H, C₁₋₄ alkyl or -CO₂C₁₋₄alkyl;

at each occurrence, C₁₋₁₀alkyl is optionally substituted with 1-3 halo, OH, CN,
5 NO₂, OC₁₋₄ alkyl, NR⁶R⁶, C(=O)C₁₋₄alkyl, OC(=O)C₁₋₄alkyl, C(=O)OC₁₋₄alkyl, phenyl or S(O)_nC₁₋₄alkyl;

at each occurrence, C₃₋₇cycloalkyl is optionally substituted with 1-3 halo, OH, CN, NO₂, C₁₋₄ alkyl, OC₁₋₄ alkyl, NR⁶R⁶, C(=O)C₁₋₄alkyl, OC(=O)C₁₋₄alkyl, C(=O)OC₁₋₄alkyl, or S(O)_nC₁₋₄alkyl;

10 at each occurrence, aryl is optionally substituted with 1-3 halo, OH, CN, NO₂, C₁₋₄alkyl, OC₁₋₄ alkyl, NR⁶R⁶, C(=O)C₁₋₄alkyl, OC(=O)C₁₋₄alkyl, C(=O)OC₁₋₄alkyl, or S(O)_nC₁₋₄alkyl;

at each occurrence het is optionally substituted with 1-3 halo, OH, CN, NO₂, C₁₋₄alkyl, OC₁₋₄ alkyl, NR⁶R⁶, C(=O)C₁₋₄alkyl, OC(=O)C₁₋₄alkyl, C(=O)OC₁₋₄alkyl,
15 S(O)_nC₁₋₄alkyl, or oxo;

and each n is independently 0-4.

In another aspect, the present invention also provides:

a pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an effective amount of a compound of formula I,

20 a method for treating gram-positive microbial infections in a mammal by administering to the subject in need a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof,

a method for treating gram-negative microbial infections in a mammal by administering to the subject in need a therapeutically effective amount of a compound
25 of formula I or a pharmaceutically acceptable salt thereof, and

a use of a compound of formula I or a pharmaceutically acceptable salt thereof to prepare a medicament for treating gram-positive or gram-negative microbial infections.

The invention may also provide some novel intermediates and processes that
30 are useful for preparing compounds of formula I.

DETAILED DESCRIPTION OF THE INVENTION

Unless otherwise stated, the following terms used in the specification and claims have the meanings given below:

The carbon atom content of various hydrocarbon-containing moieties is indicated by a prefix designating the minimum and maximum number of carbon atoms in the moiety, i.e., the prefix C_{i-j} indicates a moiety of the integer "i" to the integer "j" carbon atoms, inclusive. Thus, for example, C₁₋₇ alkyl refers to alkyl of
 5 one to seven carbon atoms, inclusive.

The term alkyl, alkenyl, etc. refer to both straight and branched groups, but reference to an individual radical such as "propyl" embraces only the straight chain radical, a branched chain isomer such as "isopropyl" being specifically referred to. Alkyl is optionally substituted with 1-3 halo, OH, CN, NO₂, OC₁₋₄ alkyl, NR⁶R⁶,
 10 C(=O)C₁₋₄alkyl, OC(=O)C₁₋₄alkyl, C(=O)OC₁₋₄alkyl, or S(O)_nC₁₋₄alkyl.

The term "cycloalkyl" refers to a cyclic saturated monovalent hydrocarbon group of three to seven carbon atoms, e.g., cyclopropyl, cyclohexyl, and the like. Cycloalkyl is optionally substituted with 1-3 halo, OH, CN, NO₂, C₁₋₄ alkyl, OC₁₋₄ alkyl, NR⁶R⁶, C(=O)C₁₋₄alkyl, OC(=O)C₁₋₄alkyl, C(=O)OC₁₋₄alkyl, or S(O)_nC₁₋₄alkyl.

15 The term "halo" refers to fluoro (F), chloro (Cl), bromo (Br), or iodo (I).

The term "aryl" refers to phenyl, biphenyl, or naphthyl, optionally substituted with 1-3 halo, OH, CN, NO₂, C₁₋₄alkyl, OC₁₋₄ alkyl, NR⁶R⁶, C(=O)C₁₋₄alkyl, OC(=O)C₁₋₄alkyl, C(=O)OC₁₋₄alkyl, or S(O)_nC₁₋₄alkyl.

The term "het" refers to an aromatic ring, or a saturated or unsaturated ring
 20 that is not aromatic, of 3 to 10 carbon atoms and 1 to 4 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur within the ring. Het is optionally substituted with 1-3 halo, OH, CN, NO₂, C₁₋₄alkyl, OC₁₋₄ alkyl, NR⁶R⁶, C(=O)C₁₋₄alkyl, OC(=O)C₁₋₄alkyl, C(=O)OC₁₋₄alkyl, S(O)_nC₁₋₄alkyl, or oxo. An examples of
 25 het includes, but are not limited to, azetidine, pyrrole, imidazole, pyrazole, 1,2,3-triazole, 1,3,4-triazole, oxazole, thiazole, isoxazole, isothiazole, 1,3,4-oxadiazole, 1,3,4-thiadiazole, 1,2,3-thiadiazole, tetrazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, dihydroindole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine, phenanthroline, isothiazole, phenazine,
 30 isoxazole, isoxazolinone, phenoxazine, phenothiazine, imidazolidine, imidazoline, piperidine, piperazine, indoline, phthalimide, 1,2,3,4-tetrahydroisoquinoline, 4,5,6,7-tetrahydrobenzo[b]thiophene, thiazole, thiadiazole tetrazole, thiazolidine, thiophene, benzo[b]thiophene, morpholine, thiomorpholine, (also referred to as thiamorpholine),

piperidine, pyrrolidine, tetrahydrofuran, or the like. Another example of het includes, but are not limited to, pyridine, thiophene, furan, pyrazole, pyrimidine, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 3-pyridazinyl, 4-pyridazinyl, 3-pyrazinyl, 4-oxo-2-imidazolyl, 2-imidazolyl, 4-imidazolyl, 3-isoxaz-
 5 olyl, 4-is-oxaz-olyl, 5-isoxaz-olyl, 3-pyrazolyl, 4-pyrazolyl, 5-pyrazolyl, 2-oxazolyl, 4-oxazolyl, 4-oxo-2-oxazolyl, 5-oxazolyl, 1,2,3-oxathiazole, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 3-isothiazole, 4-isothiazole, 5-isothiazole, 2-furanyl, 3-furanyl, 2-thienyl, 3-thienyl, 2-pyrrolyl, 3-pyrrolyl, 3-isopyrrolyl, 4-isopyrrolyl, 5-isopyrrolyl, 1,2,3-oxathiazole-1-
 10 oxide, 1,2,4-oxadiazol-3-yl, 1,2,4-oxadiazol-5-yl, 5-oxo-1,2,4-oxadiazol-3-yl, 1,2,4-thiadiazol-3-yl, 1,2,5-thiadiazol-3-yl, 1,2,4-thiadiazol-5-yl, 3-oxo-1,2,4-thiadiazol-5-yl, 1,3,4-thiadiazol-5-yl, 2-oxo-1,3,4-thiadiazol-5-yl, 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl, 1,2,3,4-tetrazol-5-yl, 5-oxazolyl, 3-isothiazolyl, 4-isothiazolyl and 5-isothiazolyl, 1,3,4-oxadiazole, 4-oxo-2-thiazolinyl, or 5-methyl-1,3,4-thiadiazol-2-yl,
 15 thiazoledione, 1,2,3,4-thiatriazole, or 1,2,4-dithiazolone

The dotted lines within the structure of formula I indicate an optional double bond at these positions.

The term "a pharmaceutically acceptable salt" of a compound means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity
 20 of the parent compound. Such salts include:

(1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid,
 25 succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]oct-2-ene-1-carboxylic acid, glucoheptonic acid, 4,4'-
 30 methylenebis-(3-hydroxy-2-ene-1-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid,

glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, and the like; or

- (2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an
- 5 aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like.

The term "pharmaceutically acceptable carrier" means a carrier that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes a carrier that is acceptable for

10 veterinary use as well as human pharmaceutical use. "A pharmaceutically acceptable carrier" as used in the specification and claims includes both one and more than one such carrier.

The term "mammal" refers to human or warm-blooded animals including livestock and companion animals.

- 15 The term "optional" or "optionally" means that the subsequently described event or circumstance may, but need not, occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not.

Compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are

20 termed "isomers". Isomers that differ in the arrangement of their atoms in space are termed "stereoisomers".

Stereoisomers that are not mirror images of one another are termed "diastereomers" and those that are non-superimposable mirror images of each other are termed "enantiomers". When a compound has an asymmetric center, for example,

25 it is bonded to four different groups, a pair of enantiomers is possible. An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R- and S-sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (i.e., as (+) or (-)-isomers respectively). A chiral

30 compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a "racemic mixture".

The compounds of this invention may possess one or more asymmetric centers; such compounds can therefore be produced as individual (R)- or (S)-

stereoisomers or as mixtures thereof. Unless indicated otherwise, the description or naming of a particular compound in the specification and claims is intended to include both individual enantiomers and mixtures, racemic or otherwise, thereof. The methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art (see discussion in Chapter 4 of "Advanced Organic Chemistry", 4th edition J. March, John Wiley and Sons, New York, 1992).

The term "treating" or "treatment" of a disease includes: (1) preventing the disease, i.e. causing the clinical symptoms of the disease not to develop in a mammal that may be exposed to or predisposed to the disease but does not yet experience or display symptoms of the disease; (2) inhibiting the disease, i.e., arresting or reducing the development of the disease or its clinical symptoms; or (3) relieving the disease, i.e., causing regression of the disease or its clinical symptoms.

The term "therapeutically effective amount" means the amount of a compound that, when administered to a mammal for treating a disease, is sufficient to effect such treatment for the disease. The "therapeutically effective amount" will vary depending on the compound, the disease and its severity and the age, weight, etc., of the mammal to be treated.

The term "leaving group" has the meaning conventionally associated with it in synthetic organic chemistry i.e., an atom or group capable of being displaced by a nucleophile and includes halogen, alkylsulfonyloxy, ester, or amino such as chloro, bromo, iodo, mesyloxy, tosyloxy, trifluorosulfonyloxy, methoxy, N,O-dimethylhydroxyl-amino, and the like.

The compounds of the present invention are generally named according to the IUPAC or CAS nomenclature system.

Abbreviations which are well known to one of ordinary skill in the art may be used (e.g. "Ph" for phenyl, "Me" for methyl, "Et" for ethyl, "h" for an hour or hours and "rt" for room temperature).

Specific and preferred values listed below for radicals, substituents, and ranges, are for illustration only; they do not exclude other defined values or other values within defined ranges for the radicals and substituents.

Specifically, alkyl denotes both straight and branched groups; but reference to an individual radical such as "propyl" embraces only the straight chain radical, a branched chain isomer such as "isopropyl" being specifically referred to.

Specifically, alkyl is methyl, ethyl, propyl, isopropyl, butyl, iso-butyl, sec-butyl, and their isomeric forms thereof.

Specifically, alkenyl is vinyl, propenyl, allyl, butenyl, and their isomeric forms thereof.

5 Specifically, cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and their isomeric forms thereof.

Specifically, halo is fluoro (F), chloro (Cl).

Specifically, R^1 is C_{1-4} alkyl, optionally substituted with one, two or three fluoro (F), or chloro (Cl).

10 Specifically, R^1 is CH_3 , or CH_2CH_3 , CHF_2 , CF_3 , or $CHCl_2$.

Specifically, R^1 is CHF_2 , CF_3 , or $CHCl_2$.

Specifically, one of the R^2 and R^3 is fluoro (F).

Specifically, R^4 is H.

Specifically, R^4 is H., or CH_3 .

15 Specifically, R^5 is C_{1-5} alkyl, optionally substituted with phenyl.

Specifically, R^5 is cyclopropane, cyclopentane, or cyclohexane.

Specifically, R^5 is phenyl.

Specifically, R^5 is an unsaturated het of 3 to 4 carbon atoms and 1 to 2 heteroatoms selected from the group consisting of O, NQ, and S within the ring,

20 wherein Q is absent, H, C_{1-4} alkyl or $-CO_2C_{1-4}$ alkyl.

Specifically, R^5 is tetrahydro-pyran, piperidine, or pyrrolidine.

Specifically, R^5 is $C(R^6)(R^7)NH_2$ wherein R^6 is H or methyl; and R^7 is H, Me, Et, iso-propyl, sec-butyl, $CH(Me)Et$, benzyl, CH_2OH , CH_2COOH , CH_2CH_2COOH , $CONH_2$, or CH_2CONH_2 .

25 Specifically, R^5 is $C(R^6)(R^7)NH_2$ wherein R^6 is H; and R^7 is C_{1-5} alkyl optionally substituted with phenyl.

Specifically, each W is independently $-CH_2-$.

Specifically, Z is $-CH-$.

Specifically, Z is $-N-$.

30 Specifically, X is $-SO_2-$.

Examples of the present invention are:

(1) ($\{[acetyl(\{(5R)-3-[4-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl\}-methyl)amino] carbonyl\}oxy\}$ methylacetate,

- (2) (R)- propionic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester,
- (3) (R)- isobutyric acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester,
- 5 (4) (R)- 3-methyl-butyric acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester,
- (5) (R)- butyric acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester,
- (6) (R)- 2,2-dimethy-propionic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester,
- 10 (7) (R)- 3,3-dimethy-butyric acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester,
- (8) (R)-cyclopropanecarboxylic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester,
- (9) (R)-cyclopentanecarboxylic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester,
- 15 (10) (R)-cyclohexanecarboxylic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester,
- (11) (R)-benzoic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester,
- 25 (12) (R)-tetrahydro-pyran-4-carboxylic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester,
- (13) (R)-tert-butoxycarbonylamino-acetic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester,
- 30 (14) 2(S)-tert-butoxycarbonylamino-propionic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(R)-ylmethyl}-carbamoyloxy)-methyl ester,

- (15) 2(*S*)-tert-butoxycarbonylamino-3-methyl-butyric acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl ester,
- (16) 2(*R*)-tert-butoxycarbonylamino-3-methyl-butyric acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl ester,
- 5 (17) 2(*S*)-tert-butoxycarbonylamino-4-methyl-pentanoic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl ester,
- (18) 2(*S*)-tert-butoxycarbonylamino-3(*S*)-methyl-pentanoic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl ester,
- 10 (19) 2(*S*)-tert-butoxycarbonylamino-3-phenyl-propionic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl ester,
- 15 (20) Pyrrolidine-1,2-dicarboxylic acid 2(*S*)-[(acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl] ester 1-tert-butyl ester,
- (21) (*R*)-(2-tert-butoxycarbonylamino-acetylamino)-acetic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester,
- 20 (22) (*R*)-amino-acetic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester hydrochloride,
- (23) 2(*S*)-amino-propionic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl ester hydrochloride,
- 25 (24) 2(*S*)-tert-butoxycarbonylamino-3-methyl-butyric acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl ester hydrochloride,
- 30 (25) 2(*R*)-amino-3-methyl-butyric acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl ester hydrochloride,

- (26) 2(*S*)-amino-4-methyl-pentanoic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl ester hydrochloride,
- (27) 2(*S*)-amino-3(*S*)-methyl-pentanoic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl ester hydrochloride,.
- (28) 2(*S*)-amino-3-phenyl-propionic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl ester hydrochloride,
- (29) Pyrrolidine-2(*S*)-carboxylic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl ester hydrochloride,
- (30) (*R*)-(2-amino-acetyl-amino)-acetic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester hydrochloride,
- (31) Acetic acid 1-(acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-ethyl ester,
- (32) (*R*)-piperidine-1,4-dicarboxylic acid 4-[(acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl] ester 1-tert-butyl ester,
- (33) (*R*)-piperidine-4-carboxylic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester hydrochloride,
- (34) 2(*R*)-phenyl-propionic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl ester,
- (35) 2(*S*)-phenyl-propionic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl ester,
- (36) Isonicotinic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl ester,
- (37) Propionic acid 1-(acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-ethyl ester,

- (38) Isonicotinic acid 1-(acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(R)-ylmethyl}-carbamoyloxy)-ethyl ester,
- (39) 2(S)-tert-butoxycarbonylamino-3(S)-methyl-pentanoic acid 1-(acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(R)-ylmethyl}-carbamoyloxy)-ethyl ester,
- (40) 2,2-dimethyl-propionic acid 1-(acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(R)-ylmethyl}-carbamoyloxy)-ethyl ester,
- (41) Preparation of 2(S)-Amino-3(S)-methyl-pentanoic acid 1-(acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(R)-ylmethyl}-carbamoyloxy)-ethyl ester hydrochloride, or
- (42) Cyclopentanecarboxylic acid 1-(acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(R)-ylmethyl}-carbamoyloxy)-ethyl ester.

15

Pharmaceutical Salts

The compound of formula I may be used in its native form or as a salt. In cases where forming a stable nontoxic acid or base salt is desired, administration of the compound as a pharmaceutically acceptable salt may be appropriate. Examples of pharmaceutically acceptable salts of the present invention include inorganic salts such as hydrochloride, hydrobromide, sulfate, nitrate, bicarbonate, carbonate salts, and organic salts such as tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate, etoglutarate, and glycerophosphate. .

Pharmaceutically acceptable salts may be obtained using standard procedures well known in the art, for example, reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion. Alkali metal (for example, sodium, potassium or lithium) or alkaline earth metal (for example calcium) salts of carboxylic acids can also be made.

Routes of Administration

The oxazolidinone antibacterial prodrugs of this invention have useful activity against a variety of organisms including, but not limiting to, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Enterococcus faecium*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Enterococcus faecalis*, *Moraxella catarrhalis* and *H.*

influenzae. In therapeutic use for treating, or combating, bacterial infections in a mammal (i.e. human and animals) an oxazolidinone prodrug of the present invention or its pharmaceutical compositions can be administered orally, parenterally, topically, rectally, transmucosally, or intestinally.

5 Parenteral administrations include indirect injections to generate a systemic effect or direct injections to the afflicted area. Examples of parenteral administrations are subcutaneous, intravenous, intramuscular, intradermal, intrathecal, intraocular, intranasal, intraventricular injections or infusions techniques.

 Topical administrations include the treatment of infectious areas or organs
10 readily accessibly by local application, such as, for example, eyes, ears including external and middle ear infections, vaginal, open wound, skins including the surface skin and the underneath dermal structures, or other lower intestinal tract. It also includes transdermal delivery to generate a systemic effect.

 The rectal administration includes the form of suppositories.

15 The transmucosal administration includes nasal aerosol or inhalation applications.

 The preferred routes of administration are oral and parenteral.

Composition/Formulation

 Pharmaceutical compositions of the present invention may be manufactured by
20 processes well known in the art, e.g., by means of conventional mixing, dissolving, granulation, dragee-making, levigating, emulsifying, encapsulating, entrapping, lyophilizing processes or spray drying.

 Pharmaceutical compositions for use in accordance with the present invention may be formulated in conventional manner using one or more physiologically
25 acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.

 For oral administration, the compounds can be formulated by combining the active compounds with pharmaceutically acceptable carriers well known in the art.
30 Such carriers enable the compounds of the invention to be formulated as tablets, pills, lozenges, dragees, capsules, liquids, solutions, emulsions, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient. A carrier can be at least one substance which may also function as a diluent, flavoring agent, solubilizer, lubricant,

suspending agent, binder, tablet disintegrating agent, and encapsulating agent.

Examples of such carriers or excipients include, but are not limited to, magnesium carbonate, magnesium stearate, talc, sugar, lactose, sucrose, pectin, dextrin, mannitol, sorbitol, starches, gelatin, cellulosic materials, low melting wax, cocoa butter or
5 powder, polymers such as polyethylene glycols and other pharmaceutical acceptable materials.

Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide,
10 lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

Pharmaceutical compositions which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a
15 plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with a filler such as lactose, a binder such as starch, and/or a lubricant such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, liquid polyethylene glycols, cremophor, capmul,
20 medium or long chain mono-, di- or triglycerides. Stabilizers may be added in these formulations, also.

Liquid form compositions include solutions, suspensions and emulsions. For example, there may be provided solutions of the compounds of this invention dissolved in water and water-propylene glycol and water-polyethylene glycol systems,
25 optionally containing suitable conventional coloring agents, flavoring agents, stabilizers and thickening agents.

The compounds may also be formulated for parenteral administration, *e.g.*, by injections, bolus injection or continuous infusion. Formulations for parenteral administration may be presented in unit dosage form, *e.g.*, in ampoules or in multi-
30 dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulating materials such as suspending, stabilizing and/or dispersing agents.

For injection, the compounds of the invention may be formulated in aqueous solution, preferably in physiologically compatible buffers or physiological saline buffer. Suitable buffering agents include trisodium orthophosphate, sodium bicarbonate, sodium citrate, N-methylglucamine, L(+)-lysine and L(+)-arginine.

5 Parenteral administrations also include aqueous solutions of a water soluble form, such as, without limitation, a salt, of the active compound. Additionally, suspensions of the active compounds may be prepared in a lipophilic vehicle. Suitable lipophilic vehicles include fatty oils such as sesame oil, synthetic fatty acid esters such as ethyl oleate and triglycerides, or materials such as liposomes. Aqueous
10 injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers and/or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

15 Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, *e.g.*, sterile, pyrogen-free water, before use. For suppository administration, the compounds may also be formulated by mixing the agent with a suitable non-irritating excipient which is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug.
20 Such materials include cocoa butter, beeswax and other glycerides.

For administration by inhalation, compounds of the present invention can be conveniently delivered through an aerosol spray in the form of solution, dry powder, or suspensions. The aerosol may use a pressurized pack or a nebulizer and a suitable propellant. In the case of a pressurized aerosol, the dosage unit may be controlled by
25 providing a valve to deliver a metered amount. Capsules and cartridges of, for example, gelatin for use in an inhaler may be formulated containing a power base such as lactose or starch.

For topical applications, the pharmaceutical composition may be formulated in a suitable ointment containing the active component suspended or dissolved in one or
30 more carriers. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutical compositions can be formulated in a

suitable lotion such as suspensions, emulsion, or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, ceteary alcohol, 2-octyldodecanol, 5 benzyl alcohol and water.

For ophthalmic and otitis uses, the pharmaceutical compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or preferably, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as a benzylalkonium chloride. Alternatively, for ophthalmic uses, 10 the pharmaceutical compositions may be formulated in an ointment such as petrolatum.

In addition to the formulations described previously, the compounds may also be formulated as depot preparations. Such long acting formulations may be in the form of implants. A compound of this invention may be formulated for this route of 15 administration with suitable polymers, hydrophobic materials, or as a sparingly soluble derivative such as, without limitation, a sparingly soluble salt.

Additionally, the compounds may be delivered using a sustained-release system. Various sustained-release materials have been established and are well known by those skilled in the art. Sustained-release capsules may, depending on their 20 chemical nature, release the compounds for 24 hours or for up to several days.

Dosage

Pharmaceutical compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in an amount sufficient to achieve the intended purpose, *i.e.*, the treatment or prevent of infectious diseases. 25 More specifically, a therapeutically effective amount means an amount of compound effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated.

The quantity of active component, that is the compound of this invention, in the pharmaceutical composition and unit dosage form thereof may be varied or 30 adjusted widely depending upon the manner of administration, the potency of the particular compound and the desired concentration. Determination of a therapeutically effective amount is well within the capability of those skilled in the art. Generally, the

quantity of active component will range between 0.5% to 90% by weight of the composition.

Generally, a therapeutically effective amount of dosage of active component will be in the range of about 0.1 to about 400 mg/kg of body weight/day, more preferably about 1.0 to about 50 mg/kg of body weight/day. It is to be understood that the dosages may vary depending upon the requirements of each subject and the severity of the bacterial infection being treated. In average, the effective amount of active component is about 200 mg to 800 mg and preferable 600 mg per day.

The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day. The sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations; such as multiple inhalations from an insufflator or by application of a plurality of drops into the eye.

Also, it is to be understood that the initial dosage administered may be increased beyond the above upper level in order to rapidly achieve the desired plasma concentration. On the other hand, the initial dosage may be smaller than the optimum and the daily dosage may be progressively increased during the course of treatment depending on the particular situation. If desired, the daily dose may also be divided into multiple doses for administration, e.g., two to four times per day.



In cases of local administration or selective uptake, the effective local concentration of the drug may not be related to plasma concentration and other procedures known in the art may be used to determine the desired dosage amount.

Oral Efficacy

Bioavailability

The present invention discovers a new type of oxazolidinone prodrug which has much improved oral bioavailability. When administered to a mammalian subject, the compounds of the present are absorbed intact and then are rapidly converted to the parent oxazolidinones. Table 1 provides single dose pharmacokinetics of example 1 of the present invention and its parent compound.

TABLE 1
Single-Dose Pharmacokinetics


Compounds	Dose mg/kg	C _{max} µg/ml	F
	10	1.0	21
	10 ^c	5.22	75

The tests were conducted in male beagle dogs, and were administered in the forms of aqueous suspension. The term “10^c” refers to an equivalent dose of the parent compound. The term “C_{max}” refers to maximum concentration achieved in the blood. It is well known that the oral efficacy is directly correlated with blood concentration. The term “F” refers to the fraction of the total dosage gets into the blood (known as bioavailability).

Methods of Preparation


The following Schemes describe the preparation of compounds of the present invention. All of the starting materials are prepared by procedures described in the scheme or by procedures that would be well known to one of ordinary skill in organic chemistry. The variables used in the Schemes are as defined below or as in the claims.

SCHEME A



- 5 Scheme A illustrates a general synthesis of acyloxymethylcarbamate prodrugs of oxazolidinones. In scheme A, the starting amine compound **a** may be prepared according to PCT international publication WO 97/09328. The starting compound **b** is either commercial available or can be prepared according to the procedures found in the literature (*Synthesis*, **1990**, 1159-1166. *ibid*, **2002**, 365-370). Compound **c** can be
- 10 prepared by reacting the starting compound **a** with structure **b** in the presence of a base such as diisopropylethylamine followed by a solution of acid chloride at a temperature about a 0°C. Reaction of compound **c** with the appropriate anhydride, such as acetic anhydride in the presence of an appropriate base such a triethylamine and a catalytic amount of dimethylaminopyridine in a suitable solvent such as
- 15 dichloromethane affords the desired compound of formula I.

SCHEME B




- Scheme B illustrates another general synthesis of acyloxymethylcarbamate prodrugs of oxazolidinones. In scheme b, the compound of structure e is either
- 5 commercially available or can be readily prepared according the methods well known to one skilled in art. Compound f can be prepared by reacting the starting compound a with acid chloride e in the presence of a base such as diisopropylethylamine. Reacting a compound of structure f with a compound of structure g in the presence of
- 10 a suitable salt such as potassium iodide or sodium iodide provides a protected compound of structure h. The compound of structure h reacts with acetyl chloride in the presence of a base such as triethyl amine, and then is treated with hydrogen chloride to provide compounds of the present invention. Specific reaction conditions of Scheme B are illustrated in Rautio, J. et. Al. Pharmaceutical Research 1999, 16(8),
- 15 1172 – 1178; Wheeler, W.J. et.al. J. Med. Chem. 1979, 22, 657-661.
- Alternatively, acyloxymethylcarbamate prodrugs of oxazolidinones can be prepared as illustrated in Scheme C. In Scheme C, compound k can be prepared by reacting the starting compound j with acid chloride e in the presence of a base such as

diisopropylethylamine or lithium t-butoide. Reacting a compound of structure **k** with a cesium salt of an appropriate N-BOC-amino acid **l** in the presence of a suitable salt such as potassium iodide or sodium iodide provides compound of structure **m**.

Hydrolysis of compound of structure **m** in an acidic condition such as using hydrogen chloride provides a compound of structure **p**. In Schemes B and C, a person of ordinary skill in the art would know how to convert a compound of hydrogen chloride into its native form.

SCHEME C



The following synthetic examples are offered to illustrate this invention and are not to be construed in any way as limiting the scope of this invention.


EXAMPLES

In the discussion above and in the examples below, the following abbreviations have the following meanings. If an abbreviation is not defined, it has its generally accepted meaning.


	bm	=	broad multiplet
	BOC	=	<i>tert</i> -butoxycarbonyl
	bd	=	broad doublet
	bs	=	broad singlet
5	CDI	=	1,1 <i>O</i> -carbodiimidazole
	d	=	doublet
	dd	=	doublet of doublets
	dq	=	doublet of quartets
	dt	=	doublet of triplets
10	DMF	=	dimethylformamide
	DMAP	=	dimethylaminopyridine
	DMSO	=	dimethyl sulfoxide
	eq.	=	equivalents
	g	=	grams
15	h	=	hours
	HPLC	=	high pressure liquid chromatography
	HATU	=	N-[(dimethylamino)-1H-1,2,3-triazolo-[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate N-oxide
20	LG	=	leaving group
	m	=	multiplet
	M	=	molar
	M%	=	mole percent
	max	=	maximum
25	meq	=	milliequivalent
	mg	=	milligram
	mL	=	milliliter
	mm	=	millimeter
	mmol	=	millimol
30	q	=	quartet
	s	=	singlet
	t or tr	=	triplet
	TBS	=	tributylsilyl
	TFA	=	trifluoroacetic acid
35	THF	=	tetrahydrofuran
	TLC	=	thin layer chromatography
	p-TLC	=	preparative thin layer chromatography
	μL	=	microliter
	N	=	normality
40	MeOH	=	methanol
	DCM	=	dichloromethane
	HCl	=	hydrochloric acid
	ACN	=	acetonitrile
	MS	=	mass spectrometry
45	rt	=	room temperature
	EtOAc	=	ethyl acetate
	EtO	=	ethoxy
	Ac	=	acetate
	NMP	=	1-methyl-2-pyrrolidinone
50	μL	=	microliter

	J	=	coupling constant
	NMR	=	Nuclear magnetic resonance
	MHz	=	megahertz
	Hz	=	hertz
5	m/z	=	mass to charge ratio
	min	=	minutes
	Boc	=	<i>tert</i> -butoxycarbonyl
	CBZ	=	benzyloxycarbonyl
	DCC	=	1,3-dicyclohexylcarbodiimide
10	PyBop	=	benzotriazole-1-yl-oxy-trispyrrolidinophosphonium hexafluorophosphate

General Procedure 1



Preparation of (*S*)-5-Aminomethyl-3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-oxazolidin-2-one (2)



Compounds 1 and 2 may be prepared according to the PCT international publication WO 97/09328. Compound 2 may also be prepared as following:

- 5 To a slurry of (S)-N-{3-[4-(1,1-Dioxo-hexahydro-1⁶-thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide (**1**) (1.4 g, 3.64 mmol) in methanol (72 mL) was added 6 N HCl (24 mL). The mixture was heated to reflux overnight. The mixture was then cooled to RT and conc *in vacuo*. Ethyl acetate and water were added to the residue and the layers were separated. The aq layer was made
- 10 basic (pH 12-13) by the addition of 2 M NaOH, and then the aq layer was extracted with ethyl acetate several times. The combined organic layers were dried over Na₂SO₄ and conc *in vacuo* to give the title compound in 72% yield (0.89 g). ¹H NMR (400 MHz, CDCl₃): δ 7.50 (dd, 1H), 7.19 (m, 2H), 4.67 (m, 1H), 4.00 (app t, 1H), 3.84 (dd, 1H), 3.15-3.05 (m, 6H), 2.95 (dd, 1H), 2.38 (m, 2H), 2.17 (m, 2H), 1.22 (br s,
- 15 2H). MS-APCI (*m/z*): 343 (M+H), 385 (M+H+CH₃CN).

- Preparation of *O*-Chloromethyl *S*-ethyl carbonothioate (**4**), *O*-iodomethyl *S*-ethyl carbonothioate (**5**), the double esters (**6**), and the acyloxymethyl carbonochloridates (**7**) may be made according to the procedures described in Lund, F.
- 20 J.; Folkmann, M. *Synthesis*, 1990, 1159-1166.

General Procedure A: Synthesis of double esters (**6**)

- The double esters (**6**) are prepared according to Lund, F. J.; Folkmann, M. *Synthesis*, 1990, 1159-1166: A mixture of sodium bicarbonate (2.68 eq),
- 25 tetrabutylammonium hydrogen sulfate (1.34 eq), water, dichloromethane, and the corresponding carboxylic acid (1.34 eq) is stirred at RT for 1 h. *O*-Iodomethyl *S*-ethyl carbonothioate (**5**) (1 eq) is then added dropwise as a solution in dichloromethane. The reaction mixture is stirred at RT overnight. The phases are separated and the aq layer is extracted twice with dichloromethane. The combined organic layers are
- 30 washed with water, dried over sodium sulfate and conc *in vacuo*. Ether is added to the

residue and the mixture is stirred for at least 1 h. The mixture is filtered and the filtrate is conc *in vacuo* to give the desired product.

General Procedure B: Synthesis of acyloxymethyl carbonochloridates (7)

5 The acyloxymethyl carbonochloridates (7) are prepared according to Lund, F. J.; Folkmann, M. *Synthesis*, 1990, 1159-1166: The appropriate thioester (6) is cooled to 0 °C and sulfonyl chloride (1 eq) is added followed by the addition of $\text{BF}_3 \cdot \text{OEt}_2$ (0.034 eq). After stirring for 1 h at 0 °C, the mixture is warmed to RT for 30 min and then conc *in vacuo* at 15 mmHg for 1 h. The resultant acyloxymethyl
10 carbonochloridates are placed under 150 mmHg vacuum overnight and then are used without further purification.

General Procedure C: Synthesis of carbamates (8)

15 A slurry of (*S*)-5-Aminomethyl-3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-oxazolidin-2-one (2) (1 eq) and CH_2Cl_2 is cooled to 0 °C. Diisopropylethyl amine (2 eq) is added dropwise, followed by the addition of the appropriate acyloxymethyl carbonochloridate (7) (1.14 eq) in CH_2Cl_2 . The mixture is stirred at 0 °C for 30-45 min and then warmed to RT. Upon completion of the reaction, water is added and the phases are separated. The organic layer is washed
20 with water, 1 N HCl, brine, dried over Na_2SO_4 , and conc *in vacuo*. Purification is achieved by silica gel chromatography.

General Procedure D: Synthesis of prodrugs (9)

25 To a solution of the appropriate carbamate (8) (1 eq) in CH_2Cl_2 is added triethylamine (2 eq), 4-dimethylaminopyridine (0.1 eq), and acetic anhydride (20 eq). The mixture is stirred at RT overnight. Water is added and the phases are separated. The organic layer is washed with sat NaHCO_3 , water, brine, dried over Na_2SO_4 , and conc *in vacuo*. After purification by silica gel chromatography, the product is re-dissolved in CH_2Cl_2 and washed three times with sat NaHCO_3 , brine, dried over
30 Na_2SO_4 and conc *in vacuo* to afford the desired product.

Example 1 Preparation of ({[acetyl({(5R)-3-[4-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl)-methyl]amino}carbonyl}oxy)methylacetate.

5 Step 1: Preparation of carbonothioic acid, O-(chloromethyl) S-ethyl ester.

To a stirred solution of chloromethyl chloroformate (3.5 mL, 38.7 mmol) in dry ether (70 mL) cooled to 0 °C is added dropwise a solution of ethane thiol (2.8 mL, 38.7 mmol) and triethylamine (5.4 mL, 38.7 mmol) in ether (15 mL) over 45 min. Stirred at 0 °C for 30 min and then at RT overnight. The reaction mixture filtered and
10 the filtrate is concentrated. The resulting oil is distilled (30 torr, 85-90 °C) to afford 4.26 g (27.6 mmol, 72%) of the desired thioester. ¹H NMR (CDCl₃) δ 5.79 (s, 2 H), 2.95 (q, *J* = 7 Hz, 2 H), 1.38 (t, *J* = 7 Hz, 2 H).

Step 2: Preparation of carbonothioic acid, S-ethyl O-(iodomethyl) ester.

15 To a stirred solution of the thioester from Step 1 (2.6 g, 16.9 mmol) in acetone (22 mL) is added sodium iodide (5.08 g 33.9 mmol) and sodium hydrogen carbonate (142.4 mg, 1.69 mmol). The reaction mixture is heated at 40 °C for 4 h. The cooled reaction mixture is filtered and the filter cake is washed with acetone and ether. The filtrate is concentrated. The resulting residue is partitioned between cold pentane (50
20 mL) and cold water (20 mL). The phases are separated. The organic phase is washed successively with a cold solution of 5% aqueous NaHCO₃ (20 mL), 10% aqueous Na₂SO₃ (10 mL), water (10 mL), dried (MgSO₄), filtered and concentrated to afford 3.86 g (15.6 mmol, 93%) of the desired iodide as a pale yellow oil. ¹H NMR (CDCl₃) δ 6.01 (s, 2 H), 2.93 (q, *J* = 7 Hz, 2 H), 1.34 (t, *J* = 7 Hz, 3 H).

25

Step 3: Preparation of carbonothioic acid, O-[(acetyloxy)methyl] S-ethyl ester.


To a stirred suspension of anhydrous sodium acetate (1.27 g, 15.60 mmol) in dry DMF (21 mL) cooled to 0 °C is added dropwise a solution of the iodide from Step 2 (3.84 g, 15.60 mmol) in DMF (3 mL) with 1 mL rinse. The reaction mixture is stirred
30 at RT overnight and then filtered. The filter cake is washed with a small amount of DMF and ether. The filtrate is partitioned between ether (100 mL) and ice cold H₂O (100 mL). The phases are separated. The aqueous phase is extracted with ether (2 x 40 mL). The combined organics are washed successively with 5% aqueous NaHCO₃

(50 mL), H₂O (50 mL), 0.1 N HCl (50 mL), H₂O (2 x 50 mL), dried (MgSO₄), filtered and concentrated. The resulting liquid is purified on a Biotage 40 S column using 100% hexane to 2% ethyl acetate in hexane as the eluent to afford 1.52 g (8.54 mmol, 55%) of the desired product. ¹H NMR (CDCl₃) δ 5.81 (s, 2 H), 2.92 (q, *J* = 10 Hz, 2 H), 2.14 (s, 3 H), 1.35 (t, *J* = 10 Hz, 3 H).

Step 4: Preparation of carbonochloridic acid, (acetyloxy)methyl ester.

To the thioester from Step 3 (2.50 g, 14.0 mmol) cooled to 0 °C is added sulfuryl chloride (1.5 mL, 18.25 mmol) over 2 min. The reaction mixture is stirred at 0 °C for 30 min then at RT for 2.5 h. The reaction mixture is concentrated and then dried on house vacuum overnight to afford 2.4 g of the desired crude product, which is used without further purification. ¹H NMR (CDCl₃) δ 5.83 (s, 2 H), 2.19 (s, 3 H);


Step 5: Preparation of (((((5S)-3-[4-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)amino]carbonyl)oxy)methyl acetate.



To a stirred suspension of the 4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]-2-fluorophenyl}tetrahydro-1λ⁶-thiopyran-1,1(2H)-dione (4.68 g, 13.74 mmol) prepared according to the PCT international publication WO 97/09328 in CH₂Cl₂ (100 mL) cooled to 0 °C is added diisopropylethylamine (4.8 mL, 27.48 mmol) followed by a solution of 2.4 g (1.57 mmol) of the acid chloride (from Step 4) in CH₂Cl₂ (10 mL) with a 2 mL rinse. The reaction mixture is stirred at 0 °C for 30 min then at RT for 3 h. The reaction mixture is partitioned between CH₂Cl₂ (300 mL) and H₂O (200 mL). The phases are separated. The organics are washed with 1N HCl (100 mL), brine (100 mL), dried (MgSO₄), filtered and concentrated. The residue is dissolved in CH₂Cl₂, absorbed onto silica gel and purified on a Biotage 40M with a SIM using 2% CH₃OH in CH₂Cl₂ as the eluent to afford 5.32 g (11.6 mmol, 85%) of the desired carbamate as a white foam. ¹H NMR (DMSO) δ 7.96 (t, *J* = 6 Hz, 1 H), 7.48 (dd, *J* = 14, 2 Hz, 1 H), 7.38 (t, *J* = 9 Hz, 1 H), 7.24 (dd, *J* = 9, 2 Hz, 1 H), 5.61

(s, 2 H), 4.74 (m, 1 H), 4.12 (t, $J = 9$ Hz, 1 H), 3.76 (dd, $J = 9, 7$ Hz, 1 H), 3.38 (m, 4 H), 3.16 (m, 1 H), 3.11 (m, 2 H), 2.13 (m, 2 H), 2.06 (m, 1 H), 2.01 (s, 3 H); ^{13}C NMR (DMSO- d_6) δ 169.3, 160.6, 158 (d, $J = 246$ Hz), 154.8, 153.8, 138.3 (d, $J = 8$ Hz), 128.1, 125.2 (d, $J = 11$ Hz), 113.7, 105.2 (d, $J = 26$ Hz), 79.3, 71.7, 54.8, 50.3, 46.8, 43.1, 33.3, 29.8, 20.4; IR (diffuse reflectance) 2415, 2351, 2328, 1921, 1916, 1753, 1744, 1515, 1411, 1292, 1247, 1223, 1121, 1010, 983 cm^{-1} . % Water (KF titration): 1.08. $[\alpha]_D^{25} = -36^\circ$ (c 0.91, DMSO). Anal. Calcd for $\text{C}_{19}\text{H}_{23}\text{FN}_2\text{O}_8\text{S}$ plus 1.08% H_2O : C, 49.24; H, 5.12; N, 6.04; S, 6.85. Found: C, 49.05; H, 5.21; N, 5.81; S, 6.85.

- 10 Step 6: Preparation of ([acetyl((5R)-3-[4-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl)-methyl)amino] carbonyl)oxy)methyl-
acetate.



- To a stirred solution of the carbamate (from Step 5) (2.64 g, 5.76 mmol) in
15 CH_2Cl_2 (60 mL) is added triethylamine (1.6 mL, 11.52 mmol) followed by DMAP
(17.5 mg) and acetic anhydride (6.5 mL, 69.15 mmol). The reaction mixture is stirred
at RT for 18 h and then additional acetic anhydride (4 mL, 42.4 mmol) is added. The
reaction mixture is stirred for an additional 24 h then partitioned between CH_2Cl_2 (200
mL) and H_2O (100 mL). The phases are separated. The organic phase is washed
20 successively with saturated aqueous NaHCO_3 (75 mL), H_2O (75 mL), brine (75 mL),
dried (MgSO_4), filtered and concentrated. The resulting residue is dissolved in
 CH_2Cl_2 , absorbed onto silica gel and purified on a Biotage 40 M with a SIM using 1%
 CH_3OH in CH_2Cl_2 as the eluent to afford 2.24 g (4.48 mmol, 78%) of the desired
product. ^1H NMR (DMSO) δ 7.43 (dd, $J = 14, 2$ Hz, 1 H), 7.38 (t, $J = 9$ Hz, 1 H), 7.28
(dd, $J = 9, 2$ Hz, 1 H), 5.72 (s, 2 H), 4.77 (m, 1 H), 4.13 (dd, $J = 18, 9$ Hz, 1 H), 4.07
25 (d, $J = 9$ Hz, 1 H), 3.89 (dd, $J = 15, 4$ Hz, 1 H), 3.80 (dd, $J = 15, 6$ Hz, 1 H), 3.37 (m,
3 H), 3.12 (m, 1 H), 3.09 (m, 2 H), 2.45 (s, 3 H), 2.14 (m, 2 H), 2.10 (s, 3 H), 2.06 (m,
2 H); IR (diffuse reflectance) 1763 (s), 1710, 1694, 1515, 1411, 1372, 1367, 1335,
1293, 1244, 1224, 1203, 1163, 1122, 1020 cm^{-1} . Anal. Calcd for $\text{C}_{21}\text{H}_{25}\text{F}\text{N}_2\text{O}_9\text{S}$:
30 C, 50.40; H, 5.03; N, 5.60; S, 6.41. Found: C, 50.22; H, 5.15; N, 5.49; S, 6.26.


Example 2 Preparation of (*R*)-propionic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester (9b).

5 Step 1: Preparation of propionic acid ethylsulfanylcarmoyloxymethyl ester (6b).

Following general procedure A, propionic acid, water (8 mL) and *O*-iodomethyl *S*-ethyl carbonothioate (5) (720 mg, 2.93 mmol) in dichloromethane (8 mL) gave the titled product in quantitative yield (562.5 mg, 2.93 mmol). ¹H NMR (400 MHz, CDCl₃): δ 5.81 (s, 2H), 2.89 (q, 2H), 2.40 (q, 2H), 1.33 (t, 3H), 1.16 (t, 3H).

Step 2: Preparation of propanoyloxymethyl carbonochloridate (7b). Following general procedure B, propionic acid ethylsulfanylcarmoyloxymethyl ester (6b) (676.9 mg, 3.52 mmol) gave the titled product in quantitative yield (586.5 mg, 3.52 mmol). ¹H NMR (400 MHz, CDCl₃): δ 5.83 (s, 2H), 2.45 (q, 2H), 1.90 (t, 3H).

Step 3: Preparation of (*S*)-propionic acid 3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethylcarbamoyloxymethyl ester (8b).




20

Following general procedure C, (*S*)-5-aminomethyl-3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-oxazolidin-2-one (2) (500 mg, 1.5 mmol), dichloromethane (14 mL) and propanoyloxymethyl carbonochloridate (7b) gave the titled product in 75% yield (520.9 mg, 1.10 mmol). ¹H NMR (400 MHz, CDCl₃): δ 7.48 (dd, 1H), 7.24 (t, 1H), 7.16 (dd, 1H), 5.74 (q, 2H), 5.28 (t, 1H), 4.77-4.83 (m, 1H), 4.05 (t, 1H), 3.79 (dd, 1H), 3.67 (ddd, 1H), 3.56 (dt, 1H), 3.12-3.18 (m, 4H), 3.10 (dt, 1H), 2.32-2.46 (m, 4H), 2.17-2.20 (m, 2H), 1.12 (t, 3H). MS-APCI (m/z+): 473 (M+H).

30

Step 4: Preparation of (*R*)-propionic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester (9b).



5

Following general procedure D, (*S*)-propionic acid 3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethylcarbamoyloxymethyl ester (8b) (467.1 mg, 0.99 mmol) in dichloromethane (9.8 mL) gave the titled product in 88% yield (446.1 mg, 0.87 mmol). ¹H NMR (400 MHz, CDCl₃): δ 7.48 (dd, 1H), 7.23 (t, 1H), 7.15 (dd, 1H), 5.88 (s, 2H), 4.79-4.86 (m, 1H), 4.20 (dd, 1H), 4.08 (t, 1H), 4.03 (dd, 1H), 3.68 (dd, 1H), 3.13-3.19 (m, 4H), 3.10 (dt, 1H), 2.58 (s, 3H), 2.35-2.49 (m, 4H), 2.17-2.22 (m, 2H), 1.17 (t, 3H). MS-APCI (m/z+): 515 (M+H).

15

Example 3 Preparation of (*R*)-isobutyric acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester (9c).

20 Step 1: Preparation of isobutyric acid ethylsulfanylcarbonyloxymethyl ester (6c).

Following general procedure A, isobutyric acid, water (8 mL) and thiocarbonic acid *O*-iodomethyl *S*-ethyl carbonothioate (5) (720.0 mg, 2.93 mmol) in dichloromethane (8 mL) gave the titled product in quantitative yield (603.5 mg, 2.93 mmol). ¹H NMR (400 MHz, CDCl₃): δ 5.81 (s, 2H), 2.90 (q, 2H), 2.60 (sept, 1H), 2.33 (t, 3H), 1.19 (d, 6H).


25

Step 2; Preparation of isobutyroyloxymethyl carbonochloridate (7c).

Following general procedure B, isobutyric acid ethylsulfanylcarbonyloxymethyl ester (6c) (603.5 mg, 2.93 mmol) gave the titled


product in 39% yield (207.0 mg, 1.15 mmol). ^1H NMR (400 MHz, CDCl_3): δ 5.83 (s, 2H), 2.65 (sept, 1H), 1.22 (d, 6H).

Step 3: Preparation of (*S*)-isobutyric acid 3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethylcarbamoyloxymethyl ester (8c).



Following general procedure C, (*S*)-5-aminomethyl-3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-oxazolidin-2-one (2) (344.1 mg, 1.00 mmol), dichloromethane (9 mL) and isobutyroyloxymethyl carbonochloridate (7c) gave the titled product in 91% yield (446.3 mg, 0.92 mmol). ^1H NMR (400 MHz, CDCl_3): δ 7.48 (dd, 1H), 7.23 (t, 1H), 7.16 (dd, 1H), 5.73 (q, 2H), 5.28 (t, 1H), 4.80 (sept, 1H), 4.05 (t, 1H), 3.79 (dd, 1H), 3.67 (ddd, 1H), 3.57 (dt, 1H), 3.12-3.19 (m, 4H), 3.09 (dt, 1H), 2.55 (sept, 1H), 2.34-2.46 (m, 2H), 2.15-2.22 (m, 2H), 1.14 (dd, 6H). MS-APCI (m/z): 487 ($M+H$).

Step 4: Preparation of (*R*)-Isobutyric acid (acetyl- { 3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl }-carbamoyloxy)-methyl ester (9c).



Following general procedure D, (*S*)-isobutyric acid 3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethylcarbamoyloxymethyl ester (8c) (384.2 mg, 0.79 mmol) in dichloromethane (8 mL) gave the titled product in 75% yield (311.5 mg, 0.59 mmol). ^1H NMR (400

MHz, CDCl₃): δ 7.48 (dd, 1H), 7.23 (t, 1H), 7.15 (dd, 1H), 5.88 (s, 2H), 4.79-4.85 (m, 1H), 4.20 (dd, 1H), 4.07 (t, 1H), 4.02 (dd, 1H), 3.69 (dd, 1H), 3.13-3.19 (m, 4H), 3.10 (dt, 1H), 2.66 (sept, 1H), 2.57 (s, 3H), 2.35-2.46 (m, 2H), 2.18-2.22 (m, 2H), 1.20 (d, 6H). MS-APCI (m/z+): 529 (M+H).

5

Example 4 Preparation of (*R*)-3-methyl-butyric acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester (9d).

10 Step 1: Preparation of 3-methyl-butyric acid ethylsulfanylcabonyloxymethyl ester (6d). Following general procedure A, 3-methyl butyric acid in water (8 mL) and *O*-iodomethyl *S*-ethyl carbonothioate (5) (720.0 mg, 2.93 mmol) in dichloromethane (8 mL) gave the titled product in quantitative yield (644.6 mg, 2.93 mmol). ¹H NMR (400 MHz, CDCl₃): δ 5.81 (s, 2H), 2.89 (q, 2H), 2.25 (d, 2H), 2.12 (sept, 1H), 1.33 (t, 3H), 0.96 (d, 6H).

15


Step 2: Preparation of 3-methyl-butyroxymethyl carbonochloridate (7d).

Following general procedure B, 3-methyl-butyric acid ethylsulfanylcabonyloxymethyl ester (6d) (644.6 mg, 2.93 mmol) gave the titled product in 87% yield (492.7 mg, 2.53 mmol). ¹H NMR (400 MHz, CDCl₃): δ 5.86 (s, 2H), 2.29 (d, 2H), 2.13 (sept, 1H), 0.98(d, 6H).

20

Step 3: Preparation of (*S*)-3-methyl-butyric acid 3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethylcarbamoyloxymethyl ester (8d).

25




Following general procedure C, (*S*)-5-aminomethyl-3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-oxazolidin-2-one (2) (760.0 mg, 2.2

30

mmol) in dichloromethane (21 mL) and 3-methyl-butyroxymethyl carbonochloridate (7d) gave the titled product in 93% yield (1030.0 mg, 2.06 mmol). ¹H NMR (400 MHz, CDCl₃): δ 7.47 (dd, 1H), 7.23 (t, 1H), 7.16 (dd, 1H), 5.73 (q, 2H), 5.37 (t, 1H), 4.76-4.82 (m, 1H), 4.05 (t, 1H), 3.78 (dd, 1H), 3.67 (ddd, 1H), 3.55 (dt, 1H), 3.12-3.19 (m, 4H), 3.09 (dt, 1H), 2.34-2.45 (m, 2H), 2.14-2.21 (m, 2H), 2.07 (sept, 1H), 0.92 (dd, 6H). MS-APCI (m/z+): 501 (M+H).

Step 4: Preparation of (R)-3-methyl-butyric acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1λ⁶-thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester (9d).



Following General Procedure D with (S)-3-methyl-butyric acid 3-[4-(1,1-dioxo-hexahydro-1λ⁶-thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethylcarbamoyloxymethyl ester (8d) (859.5 mg, 1.72 mmol) in dichloromethane (17 mL), the titled product is afforded in 86% yield (798.9 mg, 1.47 mmol). ¹H NMR (400 MHz, CDCl₃): δ 7.48 (dd, 1H), 7.23 (t, 1H), 7.15 (dd, 1H), 5.87 (s, 2H), 4.79-4.86 (m, 1H), 4.20 (dd, 1H), 4.07 (t, 1H), 4.03 (dd, 1H), 3.69 (dd, 1H), 3.15-3.19 (m, 4H), 3.10 (dt, 1H), 2.57 (s, 3H), 2.35-2.44 (m, 2H), 2.31 (d, 2H), 2.16-2.23 (m, 2H), 2.12 (sept, 1H), 0.96 (t, 6H). MS-APCI (m/z+): 543 (M+H).

Example 5 Preparation of (R)-butyric acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1λ⁶-thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester (9e).

25

Step 1: Preparation of Thiocarbonic acid O-butoxymethyl ester S-ethyl ester (6e).


Following General Procedure A, butyric acid, water (8 mL) and O-iodomethyl S-ethyl carbonothioate (5) (720.0 mg, 2.93 mmol) in dichloromethane (8 mL) gave the titled product in quantitative yield (603.5 mg, 2.93 mmol). ¹H NMR (400 MHz,

CDCl₃): δ 5.81 (s, 2H), 2.89 (q, 2H), 2.35 (t, 2H), 1.67 (q, 2H), 1.33 (t, 2H), 0.96 (t, 2H).

Step 2: Preparation of butyroyloxymethyl carbonochloridate (7e).


- 5 Following General Procedure B with thiocarbonic acid O-butoxymethyl ester S-ethyl ester (6e) (605.8 mg, 2.94 mmol), the titled product is afforded in 56% yield (296.3 mg, 1.64 mmol). ¹H NMR (400 MHz, CDCl₃): δ 5.83 (s, 2H), 2.40 (t, 2H), 1.70 (sept, 2H), 0.98 (t, 3H).

- 10 Step 3: Preparation of (*S*)-butyric acid 3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethylcarbamoyloxymethyl ester (8e).



- 15 Following general procedure C, (*S*)-5-aminomethyl-3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-oxazolidin-2-one (2) (492.7 mg, 1.44 mmol) in dichloromethane (13 mL) and butyroyloxymethyl carbonochloridate (7e) gave the titled product in 73% yield (512.1 mg, 1.05 mmol). ¹H NMR (400 MHz, CDCl₃): δ 7.48 (dd, 1H), 7.23 (t, 1H), 7.16 (dd, 1H), 5.73 (q, 2H), 5.29 (t, 1H), 4.80 (sept, 1H), 4.05 (t, 1H), 3.79 (dd, 1H), 3.67 (ddd, 1H), 3.56 (dt, 1H), 3.13-3.19 (m, 4H), 3.09 (dt, 1H), 2.35-2.47 (m, 2H), 2.31 (t, 2H), 2.14-2.22 (m, 2H), 1.63 (q, 2H), 0.93 (t, 3H). MS-APCI (m/z+): 487 (M+H).
- 20

- Step 4: Preparation of (*R*)-butyric acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester (9e).
- 25



Following General Procedure D with (*S*)-butyric acid 3-[4-(1,1-dioxo-hexahydro-1λ⁶-thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethylcarbamoyloxymethyl ester (8e) (406.1 mg, 0.84 mmol) in dichloromethane (8.3 mL), the titled product is afforded in 91% yield (402.9 mg, 0.76 mmol). ¹H NMR (400 MHz, CDCl₃): δ 7.48 (dd, 1H), 7.23 (t, 1H), 7.15 (dd, 1H), 5.87 (s, 2H), 4.79-4.84 (m, 1H), 4.20 (dd, 1H), 4.07 (t, 1H), 4.03 (ddd, 1H), 3.68 (dd, 1H), 3.13-3.19 (m, 4H), 3.10 (dt, 1H), 2.57 (s, 3H), 2.35-2.46 (m, 2H), 2.41 (t, 2H), 2.14-2.22 (m, 2H), 1.68 (sext, 2H), 0.96 (t, 3H). MS-APCI (m/z+): 529 (M+H).

Example 6 Preparation of (*R*)-2,2-dimethyl-propionic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1λ⁶-thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester (9f).

15


Step 1: Preparation of 2,2-dimethyl-propionic acid ethylsulfanylcarmoyloxymethyl ester (6f).

Following General Procedure A, 2,2-dimethyl-propionic acid, water (8 mL) and *O*-iodomethyl *S*-ethyl carbonothioate (5) (720.0 mg, 2.93 mmol) in dichloromethane (8 mL) gave the titled product in quantitative yield (644.6 mg, 2.93 mmol). ¹H NMR (400 MHz, CDCl₃): δ 5.81 (s, 2H), 2.89 (q, 2H), 1.32 (t, 3H), 1.22 (s, 9H).

Step 2: Preparation of 2,2-dimethyl-propanoyloxymethyl carbonochloridate (7f).

Following General Procedure B with 2,2-dimethyl-propionic acid ethylsulfanylcarmoyloxymethyl ester (6f) (644.6 mg, 2.93 mmol), the titled product is afforded in 54% yield (305.4 mg, 1.57 mmol). ¹H NMR (400 MHz, CDCl₃): δ 5.83 (s, 2H), 1.25 (s, 9H).

Step 3: Preparation of (*S*)-2,2-dimethyl-propionic acid 3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethylcarbamoyloxymethyl ester (8f).




5

Following general procedure C, (*S*)-5-aminomethyl-3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-oxazolidin-2-one (2) (472.0 mg, 1.38 mmol) in dichloromethane (13 mL) and 2,2-dimethyl-propanoyloxymethyl carbonochloridate (7f) gave the titled product in 85% yield (585.6 mg, 1.17 mmol). ¹H NMR (400 MHz, CDCl₃): δ 7.47 (dd, 1H), 7.22 (t, 1H), 7.15 (dd, 1H), 5.72 (q, 2H), 5.39 (t, 1H), 4.75-4.82 (m, 1H), 4.05 (t, 1H), 3.79 (dd, 1H), 3.66 (ddd, 1H), 3.57 (dt, 1H), 3.12-3.19 (m, 4H), 3.09 (dt, 1H), 2.34-2.45 (m, 2H), 2.16-2.20 (m, 2H), 1.16 (s, 9H). MS-APCI (m/z+): 501 (M+H).

15

Step 4: Preparatio of (*R*)-2,2-dimethyl-propionic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester (9f).



20

Following General Procedure D with (*S*)-2,2-dimethyl-propionic acid 3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethylcarbamoyloxymethyl ester (8f) (450.5 mg, 0.900 mmol) in dichloromethane (9 mL), the titled product is afforded in 86% yield (422.3 mg, 0.78 mmol). ¹H NMR (400 MHz, CDCl₃): δ 7.50 (dd, 1H), 7.23 (t, 1H), 7.15 (dd, 1H), 5.87 (s, 2H), 4.78-4.85 (m, 1H), 4.20 (dd, 1H), 4.07 (t, 1H), 4.01 (dd, 1H), 3.70 (dd, 1H), 3.13-3.19 (m,

4H), 3.09 (dt, 1H), 2.56 (s, 3H), 2.35-2.46 (m, 2H), 2.15-2.21 (m, 2H), 1.23 (s, 9H).

MS-APCI (m/z+): 529 (M+H).

Example 7 Preparation of (*R*)-3,3-dimethyl-butyric acid (acetyl-{3-[4-(1,1-dioxo-
5 hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-
carbamoyloxy)-methyl ester (9g).


Step 1: Preparation of 3,3-dimethyl-butyric acid ethylsulfanylcabonyloxymethyl ester (6g). Following General Procedure A, 3,3-dimethyl-butyric acid, water (5 mL) and
10 *O*-iodomethyl *S*-ethyl carbonothioate (5) (488.2 mg, 1.98 mmol) in dichloromethane (5 mL) gave the titled product in quantitative yield (464.9 mg, 1.98 mmol). ^1H NMR (400 MHz, CDCl_3): δ 5.80 (s, 2H), 2.89 (q, 2H), 2.25 (s, 2H), 1.32 (t, 2H), 1.03 (s, 9H).

15 Step 2: Preparation of 3,3-dimethyl-butyroxymethyl carbonochloridate (7g).

Following General Procedure B with 3,3-dimethyl-butyric acid ethylsulfanylcabonyloxymethyl ester (6g) (488.2 mg, 1.98 mmol), the titled product is afforded in quantitative yield (464.9 mg, 1.98 mmol). ^1H NMR (400 MHz, CDCl_3): δ 5.82 (s, 2H), 2.27 (s, 2H), 1.05 (s, 9H).

20

Step 3: Preparation of (*S*)-3,3-dimethyl-butyric acid 3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethylcarbamoyloxymethyl ester (8g).




25

Following general procedure C, (*S*)-5-aminomethyl-3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-oxazolidin-2-one (2) (589.0 mg, 1.72 mmol) in dichloromethane (14 mL) and 3,3-dimethyl-butyroxymethyl
30 carbonochloridate (7g) gave the titled product in 46% yield (407.2 mg, 0.79 mmol).

¹H NMR (400 MHz, CDCl₃): δ 7.48 (dd, 1H), 7.24 (t, 1H), 7.16 (dd, 1H), 5.73 (q, 2H), 5.26 (t, 1H), 4.75-4.82 (m, 1H), 4.05 (t, 1H), 3.78 (dd, 1H), 3.68 (ddd, 1H), 3.56 (dt, 1H), 3.13-3.19 (m, 4H), 3.10 (dt, 1H), 2.35-2.46 (m, 2H), 2.16-2.25 (m, 4H), 1.00 (s, 9H).

5

Step 4: Preparation of (*R*)-3,3-dimethyl-butyric acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1λ⁶-thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester (9g).



10

Following General Procedure D, (*S*)-3,3-dimethyl-butyric acid 3-[4-(1,1-dioxo-hexahydro-1λ⁶-thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethylcarbamoyloxymethyl ester (8g) (330.8 mg, 0.64 mmol) in dichloromethane (6.5 mL) gave the titled product in 90% yield (329.1 mg, 0.59 mmol). ¹H NMR (400 MHz, CDCl₃): δ 7.48 (dd, 1H), 7.23 (t, 1H), 7.15 (dd, 1H), 5.86 (s, 2H), 4.78-4.85 (m, 1H), 4.20 (dd, 1H), 4.07 (t, 1H), 4.01 (dd, 1H), 3.69 (dd, 1H), 3.13-3.19 (m, 4H), 3.09 (dt, 1H), 2.57 (s, 3H), 2.34-2.48 (m, 2H), 2.30 (s, 2H), 2.14-2.22 (m, 2H), 1.03 (s, 9H). MS-APCI (m/z+): 577 (M+H).

15

20 Example 8 Preparation of (*R*)-cyclopropanecarboxylic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1λ⁶-thiopyran-4-yl)-3-fluoro-phenyl]-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester (9h).

Step 1: Preparation of cyclopropanecarboxylic acid ethylsulfanylcarmoyloxymethyl ester (6h).

25


Following General Procedure A, cyclopropanecarboxylic acid, water (8 mL) and *O*-iodomethyl *S*-ethyl carbonothioate (5) (866.5 mg, 3.52 mmol) in dichloromethane (8 mL) gave the titled product in quantitative yield (719.2 mg, 3.52

mmol). ^1H NMR (400 MHz, CDCl_3): δ 5.80 (s, 2H), 2.90 (q, 2H), 1.66 (tt, 1H), 1.33 (t, 3H), 1.07 (dt, 2H), 0.94 (dt, 2H).

Step 2: Preparation of cyclopropanecarbonylmethyl carbonochloridate (7h).

- 5 Following General Procedure B with cyclopropanecarboxylic acid ethylsulfanylcarmoyloxymethyl ester (6h) (719.2 mg, 3.52 mmol), the titled product is afforded in quantitative yield (628.8 mg, 3.52 mmol). ^1H NMR (400 MHz, CDCl_3): δ 5.82 (s, 2H), 1.66-1.71 (m, 1H), 1.10-1.14 (m, 2H), 0.98-1.03 (m, 2H).

- 10 Step 3: Preparation of (*S*)-cyclopropanecarboxylic acid 3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethylcarbamoxyloxymethyl ester (8h).




15

Following general procedure C, (*S*)-5-aminomethyl-3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-oxazolidin-2-one (500.0 mg, 1.46 mmol) (2) in dichloromethane (14 mL) and cyclopropanecarbonylmethyl carbonochloridate (7h) gave the titled product in 90% yield (637.4 mg, 1.32 mmol).

- 20 ^1H NMR (400 MHz, CDCl_3): δ 7.48 (dd, 1H), 7.23 (t, 1H), 7.16 (dd, 1H), 5.72 (q, 2H), 5.33 (t, 1H), 4.77-4.83 (m, 1H), 4.05 (t, 1H), 3.79 (dd, 1H), 3.67 (ddd, 1H), 3.56 (dt, 1H), 3.12-3.18 (m, 4H), 3.09 (dt, 1H), 2.34-2.46 (m, 2H), 2.16-2.22 (m, 2H), 1.58-1.65 (m, 1H), 1.00-1.04 (m, 2H), 0.88-0.92 (m, 2H). MS-APCI (m/z): 485 ($M+H$).

- 25 Step 4: Preparation of (*R*)-cyclopropanecarboxylic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-oxazolidin-5-ylmethyl}-carbamoxyloxy)-methyl ester (9h).



Following General Procedure D, (*S*)-cyclopropanecarboxylic acid 3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethylcarbamoyloxymethyl ester (8h) (535.8 mg, 1.11 mmol) in dichloromethane (11 mL) gave the titled product in 77% yield (445.6 mg, 0.85). ^1H NMR (400 MHz, CDCl_3): δ 7.48 (dd, 1H), 7.23 (t, 1H), 7.16 (dd, 1H), 5.87 (q, 2H), 4.79-4.86 (m, 1H), 4.20 (dd, 1H), 4.07 (t, 1H), 4.02 (dd, 1H), 3.69 (dd, 1H), 3.12-3.18 (m, 4H), 3.09 (dt, 1H), 2.58 (s, 3H), 2.35-2.46 (m, 2H), 2.16-2.23 (m, 2H), 1.70 (ttt, 1H), 1.07-1.11 (m, 2H), 0.95-1.00 (m, 2H). MS-APCI (m/z): 527 ($M+H$).

Example 9 Preparation of (*R*)-cyclopentanecarboxylic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester (9i).


Step 1: Preparation of cyclopentanecarboxylic acid ethylsulfanylcabonyloxymethyl ester (6i).

Following General Procedure A, cyclopentanecarboxylic acid, water (8 mL) and *O*-iodomethyl *S*-ethyl carbonothioate (5) (866.5 mg, 3.52 mmol) in dichloromethane (8 mL) gave the titled product in quantitative yield (818.0 mg, 3.52 mmol). ^1H NMR (400 MHz, CDCl_3): δ 5.81 (s, 2H), 2.80 (q, 2H), 2.79 (quint, 1H), 1.55-1.95 (m, 8H), 1.33 (t, 3H).

Step 2: Preparation of cyclopentanecarboxylic acid ethylsulfanylcabonyloxymethyl carbonochloridate (7i).

Following General Procedure B with cyclopentanecarboxylic acid ethylsulfanylcabonyloxymethyl ester (6i) (818.0 mg, 3.52 mmol), the titled product is afforded in quantitative yield (727.6 mg, 3.52 mmol). ^1H NMR (400 MHz, CDCl_3): δ 5.83 (s, 2H), 2.83 (quint, 1H), 1.56-1.98 (m, 8H).


Step 3: Preparation of (*S*)-cyclopentanecarboxylic acid 3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethylcarbamoyloxymethyl ester (8i).



5 Following general procedure C, (*S*)-5-aminomethyl-3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-oxazolidin-2-one (2) (500.0 mg, 1.5 mmol) in dichloromethane (14 mL) and cyclopentanecarbonoylmethyl carbonochloridate (7i) gave the titled product in 86% yield (642.2 mg, 1.25 mmol).

10 ¹H NMR (400 MHz, CDCl₃): δ 7.48 (dd, 1H), 7.23 (t, 1H), 7.16 (dd, 1H), 5.73 (q, 2H), 5.31 (t, 1H), 4.76-4.82 (m, 1H), 4.05 (t, 1H), 3.79 (dd, 1H), 3.67 (ddd, 1H), 3.57 (dt, 1H), 3.12-3.18 (m, 4H), 3.09 (dt, 1H), 2.73 (quint, 1H), 2.34-2.45 (m, 2H), 2.16-2.21 (m, 2H), 1.52-1.88 (m, 8H).

15 Step 4: Preparation of (*R*)-cyclopentanecarboxylic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester (9i).



20 Following General Procedure D with (*S*)-cyclopentanecarboxylic acid 3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethylcarbamoyloxymethyl ester (8i) (558.8 mg, 1.09 mmol) in dichloromethane (11 mL), the titled product is afforded in 88% yield (483.1 mg, 0.87 mmol). ¹H NMR (400 MHz, CDCl₃): δ 7.48 (dd, 1H), 7.23 (t, 1H), 7.15 (dd, 1H), 5.87 (q, 2H), 4.79-4.86 (m, 1H), 4.20 (dd, 1H), 4.07 (t, 1H), 4.02 (dd, 1H), 3.69 (dd, 1H), 3.13-3.19 (m, 4H), 3.10 (dt, 1H), 2.83 (ttt, 1H), 2.57 (s, 3H), 2.35-2.47 (m, 2H), 2.15-2.23 (m, 2H),

25

1.88-1.98 (m, 2H), 1.75-1.86 (m, 2H), 1.65-1.74 (m, 2H), 1.56-1.64 (m, 2H). MS-APCI (m/z+): 555 (M+H).

Example 10 Preparation of (R)-cyclohexanecarboxylic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ ⁶-thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester (9j).


Step 1: Preparation of cyclohexanecarboxylic acid ethylsulfanylcarbonyloxymethyl ester (6j).

10 Following General Procedure A, cyclohexanecarboxylic acid, water (5 mL) and O-iodomethyl S-ethyl carbonothioate (5) (488.2 mg, 1.98 mmol) in dichloromethane (5 mL) gave the titled product in quantitative yield (488.7 mg, 1.98 mmol). ¹H NMR (400 MHz, CDCl₃): δ 5.80 (s, 2H), 2.89 (q, 2H), 2.23-2.38 (m, 1H), 1.88-1.96 (m, 2H), 1.72-1.80 (m, 2H), 1.60-1.70 (m, 2H), 1.40 (m, 2H), 1.32 (t, 3H),
15 1.21-1.30 (m, 2H).

Step 2: Preparation of cyclohexanecarboxymethyl carbonochloridate (7j).

Following General Procedure B with cyclohexanecarboxylic acid ethylsulfanylcarbonyloxymethyl ester (6j) (488.2 mg, 1.98 mmol), the titled product is
20 afforded in quantitative yield (488.7 mg, 1.98 mmol). ¹H NMR (400 MHz, CDCl₃): δ 5.82 (s, 2H), 2.37 (qt, 1H), 1.90-1.98 (m, 2H), 1.72-1.81 (m, 2H), 1.60-1.78 (m, 2H), 1.41-1.53 (m, 2H), 1.22-1.36 (m, 2H).


Step 3: Preparation of (S)-cyclohexanecarboxylic acid 3-[4-(1,1-dioxo-hexahydro-1 λ ⁶-thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethylcarbamoyloxymethyl ester (8j).



Following general procedure C, (S)-5-aminomethyl-3-[4-(1,1-dioxo-hexahydro-1 λ ⁶-thiopyran-4-yl)-3-fluoro-phenyl]-oxazolidin-2-one (2) (589.0 mg, 1.72
30

mmol) in dichloromethane (14 mL) and cyclohexanecarbonylmethyl carbonochloridate (7j) gave the titled product in 80% yield (722.9 mg, 1.37 mmol).
¹H NMR (400 MHz, CDCl₃): δ 7.48 (dd, 1H), 7.23 (t, 1H), 7.16 (dd, 1H), 5.72 (q, 2H), 5.29 (t, 1H), 4.76-4.82 (m, 1H), 4.05 (t, 1H), 3.78 (dd, 1H), 3.64-3.70 (m, 1H),
 5 3.57 (dt, 1H), 3.13-3.19 (m, 4H), 3.09 (dt, 1H), 2.29-2.46 (m, 4H), 2.16-2.22 (m, 2H), 1.58-1.98 (m, 5H).

Step 4: Preparation of (*R*)-cyclohexanecarboxylic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1λ⁶-thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester (9j).
 10



Following General Procedure D with (*S*)-cyclohexanecarboxylic acid 3-[4-(1,1-dioxo-hexahydro-1λ⁶-thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethylcarbamoyloxymethyl ester (8j) (507.4 mg, 0.96 mmol) in dichloromethane (9.8 mL), the titled product is afforded in 54% yield (298.5 mg, 0.52 mmol). ¹H NMR (400 MHz, CDCl₃): δ 7.48 (dd, 1H), 7.23 (t, 1H), 7.15 (dd, 1H), 5.87 (s, 2H), 4.78-4.85 (m, 1H), 4.20 (dd, 1H), 4.07 (t, 1H), 4.01 (dd, 1H), 3.67 (dd, 1H), 3.13-3.19 (m, 4H), 3.10 (dt, 1H), 2.57 (s, 3H), 2.35-2.46 (m, 3H), 2.15-2.23 (m, 2H), 1.90-1.96 (m, 2H), 1.72-1.78 (m, 2H), 1.63-1.66 (m, 1H), 1.40-1.50 (m, 2H), 1.19-1.34 (m, 3H).
 20 MS-APCI (m/z+): 569 (M+H).
 MS-APCI (m/z+): 569 (M+H).

Example 11 Preparation of (*R*)-benzoic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1λ⁶-thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester (9k).
 25

Step 1: Preparation of benzoic acid ethylsulfanylcarmonyloxymethyl ester (6k).

Following General Procedure A with benzoic acid, water (8 mL) and *O*-iodomethyl *S*-ethyl carbonothioate (5) (866.5 mg, 3.52 mmol) in dichloromethane (8
 30


mL), the titled product is afforded in quantitative yield (846.1 mg, 3.52 mmol). ¹H NMR (400 MHz, CDCl₃): δ 8.08 (d, 2H), 7.90 (t, 1H), 7.46 (t, 2), 6.06 (s, 2H), 2.91 (q, 2H), 1.33 (t, 3H).

5 Step 2: Preparation of benzoyloxymethyl carbonochloridate (7k).

Following General Procedure B with benzoic acid ethylsulfanylcabonyloxymethyl ester (6k) (846.1 mg, 3.52 mmol), the titled product is afforded in quantitative yield (755.7 mg, 3.52 mmol). ¹H NMR (400 MHz, CDCl₃): δ 8.10 (d, 2H), 7.64 (t, 1H), 7.49 (t, 2H), 6.80 (s, 2H).


10

Step 3: Preparation of (*S*)-benzoic acid 3-[4-(1,1-dioxo-hexahydro-1λ⁶-thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethylcarbamoyloxymethyl ester (8k).



15 Following general procedure C, (*S*)-5-aminomethyl-3-[4-(1,1-dioxo-hexahydro-1λ⁶-thiopyran-4-yl)-3-fluoro-phenyl]-oxazolidin-2-one (2) (500.0 mg, 1.5 mmol) in dichloromethane (14 mL) and benzoyloxymethyl carbonochloridate (7k) gave the titled product in 98% yield (744.5 mg, 1.43 mmol). ¹H NMR (400 MHz, CDCl₃): δ 8.05 (d, 2H), 7.60 (t, 1H), 7.46 (q, 3H), 7.20 (t, 1H), 7.13 (dd, 1H), 5.98 (q, 2H), 5.36 (t, 1H), 4.77-4.83 (m, 1H), 4.05 (t, 1H), 3.80 (dd, 1H), 3.68 (ddd, 1H), 3.57
20 (dt, 1H), 3.12-3.19 (m, 4H), 3.08 (dt, 1H), 2.31-2.45 (m, 2H), 2.13-2.21 (m, 2H).

Step 4 : Preparation of (*R*)-benzoic acid (acetyl)-{3-[4-(1,1-dioxo-hexahydro-1λ⁶-thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-
25 methyl ester (9k).



Following General Procedure D with (*S*)-propionic acid 3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethylcarbamoyloxymethyl ester (8k) (604.6 mg, 1.18 mmol) in dichloromethane (12 mL), the titled product is afforded in 86% yield (564.7 mg, 1.12 mmol). ¹H NMR (400 MHz, CDCl₃): δ 8.09 (dd, 2H), 7.63 (tt, 1H), 7.44-7.50 (m, 3H), 7.20 (t, 1H), 7.12 (dd, 1H), 6.12 (q, 2H), 4.80-4.87 (m, 1H), 4.23 (dd, 1H), 4.07 (t, 1H), 4.03 (dd, 1H), 3.69 (dd, 1H), 3.12-3.18 (m, 4H), 3.09 (dt, 1H), 2.58 (s, 3H), 2.34-2.45 (m, 2H), 2.15-2.23 (m, 2H).

Example 12 Preparation of (*R*)-tetrahydro-pyran-4-carboxylic acid (acetyl-[3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl]-carbamoyloxy)-methyl ester (9l).

Step 1: Preparation of tetrahydro-pyran-4-carboxylic acid ethylsulfanylcarbonyloxymethyl ester (6l).


Following General Procedure A with tetrahydro-pyran-4-carboxylic acid, water (5 mL), *O*-iodomethyl *S*-ethyl carbonothioate (5) (488.2 mg, 1.98 mmol) in dichloromethane (5 mL), the titled product is afforded in quantitative yield (481.8 mg, 1.98 mmol). ¹H NMR (400 MHz, CDCl₃): δ 5.82 (s, 2H), 3.96 (dt, 2H), 3.43 (td, 2H), 2.90 (q, 2H), 2.57-2.65 (m, 1H), 1.76-1.90 (m, 4H), 1.33 (t, 3H).

Step 2: Preparation of tetrahydro-pyran-4-carboxylmethyl carbonochloridate (7l).

Following General Procedure B with tetrahydro-pyran-4-carboxylic acid ethylsulfanylcarbonyloxymethyl ester (6l) (488.2 mg, 1.98 mmol), the titled product is afforded in 98% yield (481.8 mg, 1.98 mmol). ¹H NMR (400 MHz, CDCl₃): δ 5.85 (s, 2H), 3.98 (dt, 2H), 3.45 (td, 2H), 2.66 (tt, 1H), 1.76-1.91 (m, 4H).

Step 3: Preparation of (*S*)-tetrahydro-pyran-4-carboxylic acid 3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethylcarbamoyloxymethyl ester (8l).

5




Following general procedure C, (*S*)-5-aminomethyl-3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-oxazolidin-2-one (2) (579.0 mg, 1.69 mmol) in dichloromethane (14 mL) and tetrahydro-pyran-4-carboxylmethyl carbonochloridate (7l) gave the titled product in 80% yield (716.5 mg, 1.36 mmol).
¹H NMR (400 MHz, CDCl₃): δ 7.48 (dd, 1H), 7.24 (t, 1H), 7.16 (dd, 1H), 5.72 (q, 2H), 5.38 (t, 1H), 4.76-4.84 (m, 1H), 4.06 (t, 1H), 3.93 (dq, 2H), 3.78 (dd, 1H), 3.68 (ddd, 1H), 3.55 (dt, 1H), 3.55 (dt, 2H), 3.14-3.19 (m, 4H), 3.10 (dt, 1H), 2.57 (tt, 1H), 2.34-2.47 (m, 2H), 2.17-2.22 (m, 2H), 1.69-1.86 (m, 4H). MS-APCI (*m/z*⁺): 529 (M+H).

15

Step 4: Preparation of (*R*)-tetrahydro-pyran-4-carboxylic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester (9l).

20




Following General Procedure D with (*S*)-tetrahydro-pyran-4-carboxylic acid 3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethylcarbamoyloxymethyl ester (8l) (627.2 mg, 1.19 mmol) in dichloromethane (12 mL), the titled product is afforded in 90% yield (610.7 mg, 1.07 mmol). ¹H NMR

25


(400 MHz, CDCl₃): δ 7.48 (dd, 1H), 7.24 (t, 1H), 7.14 (dd, 1H), 5.89 (s, 2H), 4.78-4.86 (m, 1H), 4.18 (dd, 1H), 4.08 (t, 1H), 4.04 (dd, 1H), 3.92-4.00 (m, 2H), 3.68 (dd, 1H), 3.43 (t, 2H), 3.13-3.20 (m, 4H), 3.10 (dt, 1H), 2.69 (tt, 1H), 2.57 (s, 3H), 2.35-2.46 (m, 2H), 2.17-2.24 (m, 2H), 1.51-1.84 (m, 4H). MS-APCI (m/z+): 529 (M+H).

5

General Procedure 2




- 10 Preparation of (*R*)-acetyl-{3-[4-(1,1-dioxo-hexahydro-1λ⁶-thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamic acid chloromethyl ester (10).



- 15 (*S*)-N-{3-[4-(1,1-Dioxo-hexahydro-1λ⁶-thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide (1) (2.0 g, 5.2 mmol) in 13 mL of CH₂Cl₂ and 13 mL of CH₃CN is cooled to 0 °C. Lithium t-butoxide (1.0 M in hexanes, 5.7 mL,

5.7 mmol) is added and the mixture is stirred at 0 °C for 25 min and then at RT for 10 min. The mixture is re-cooled to 0 °C and chloromethyl chloroformate (0.6 mL, 6.2 mmol) is added dropwise. The mixture is stirred for 10 min at 0 °C and then allowed to stir at RT overnight. The solution is diluted with CH₂Cl₂ and water and the layers are separated. The organic layer is washed with water, brine, dried over Na₂SO₄, and conc *in vacuo*. Purification by silica gel chromatography afforded the title compound in 74% yield (1.8 g). ¹H NMR (400 MHz, CDCl₃): δ 7.47 (dd, 1H), 7.22 (t, 1H), 7.13 (dd, 1H), 5.91 (d, 1H), 5.76 (d, 1H), 4.82 (m, 1H), 4.16 (m, 1H), 4.07 (m, 2H), 3.69 (dd, 1H), 3.10 (m, 5H), 2.58 (s, 3H), 2.38 (m, 2H), 2.17 (m, 2H). MS-APCI (*m/z* +): 341, 385, 477.

Preparation of (*R*)-acetyl-{3-[4-(1,1-dioxo-hexahydro-1λ⁶-thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamic acid 1(*R,S*)-chloro-ethyl ester (11).




(*S*)-N-{3-[4-(1,1-Dioxo-hexahydro-1λ⁶-thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide (1) (0.4 g, 1.0 mmol) in 2.5 mL of CH₂Cl₂ and 2.5 mL of CH₃CN is cooled to 0 °C. Lithium t-butoxide (1.0 M in hexanes, 1.1 mL, 1.1 mmol) is added and the mixture is stirred at 0 °C for 15 min and then at RT for 10 min. The mixture is re-cooled to 0 °C and 1-chloroethyl chloroformate (0.13 mL, 1.2 mmol) is added dropwise. The mixture is stirred for 10 min at 0 °C and then allowed to stir at RT overnight. The solution is diluted with CH₂Cl₂ and water and the layers are separated. The organic layer is washed with water, brine, dried over Na₂SO₄, and conc *in vacuo*. Purification by silica gel chromatography afforded the title compound in 64% yield (0.31 g) as a mixture of two diastereomers in a 1:1 ratio. ¹H NMR (400 MHz, CDCl₃): δ 7.46 (m, 1H), 7.22 (m, 1H), 7.13 (m, 1H), 6.57 (m, 1H), 4.82 (m, 1H), 4.22-4.02 (m, 3H), 3.73 (m, 0.5H), 3.68 (dd, 0.5H), 3.10 (m, 5H), 2.58 (s, 1.5H),

2.56 (s, 1.5H), 2.38 (m, 2H), 2.17 (m, 2H), 1.87 (app t, 3H). MS-APCI (m/z): 341, 385, 491.

General Procedure E: Formation of Cesium Salts of *N*-BOC-Amino Acids (15)

5



The procedure of Hegedus, L. S., *J. Org. Chem.* 1992, 57, 5453-5462 is used: The appropriate *N*-BOC-amino acid (14) (5.7 mmol) is dissolved in 24 mL of methanol and 2.4 mL of water. A 20% (w/w) aq solution of Cs_2CO_3 is added dropwise until the solution is titrated to pH 7 (as measured by pH paper). The solution is conc *in vacuo* and then re-evaporated twice from toluene. The resultant cesium salt is dried under full vacuum at 40 °C overnight and is used without further purification.

15

General Procedure F: Formation of *N*-BOC-Amino Acid Prodrugs (12)

(*R*)-Acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamic acid chloromethyl ester (10) (1 eq), the cesium salt of the appropriate *N*-BOC-amino acid (15) (1.55 eq), sodium iodide (1 eq), and acetonitrile are heated to reflux (82 °C) overnight. The mixture is then cooled to RT, filtered, and rinsed with CH_2Cl_2 . The filtrate is diluted with CH_2Cl_2 and water and the layers are separated. The organic layer is washed with water, 10% $\text{Na}_2\text{S}_2\text{O}_3$, water, brine, dried over Na_2SO_4 and conc *in vacuo*. Purification is accomplished by silica gel chromatography.


25

General Procedure G: Formation of Amino Acid Prodrugs as HCl salt (13)

The appropriate *N*-BOC-amino acid prodrug (12) (1 eq), anisole and THF are cooled to 0 °C. Hydrogen chloride (4 M in dioxane, 30 eq) is added dropwise. The mixture is then allowed to warm up to RT overnight. Ether is added dropwise to the mixture while stirring, resulting in the formation of a solid. The solid is collected via filtration, rinsed with ether, and dried under vacuum.

30

Example 13 Preparation of (*R*)-tert-butoxycarbonylamino-acetic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester (12a).




5

Following general procedure F, (*R*)-acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester (10) (0.4 g, 0.84 mmol), the cesium salt of *N*-BOC-glycine (15a) (0.4 g, 1.3 mmol), sodium iodide (0.13 g, 0.84 mmol), and 24 mL of acetonitrile gave the title compound in 74% yield (0.38 g). MS-APCI (*m/z*⁺): 516, 616.

Example 14 Preparation of 2(*S*)-tert-butoxycarbonylamino-propionic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl ester (12b).

15




Following general procedure F, (*R*)-acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester (10) (0.92 g, 1.9 mmol), the cesium salt of *N*-BOC-L-alanine (15b) (0.96 g, 3.0 mmol), sodium iodide (0.29, 1.9 mmol), and 50 mL of acetonitrile gave the title compound in 85% yield (1.03 g). ¹H NMR (400 MHz, CDCl₃): δ 7.46 (d, 1H), 7.21 (m, 1H), 7.13 (d, 1H), 5.89 (app s, 2H), 5.07 (br d, 1H), 4.81 (m, 1H), 4.31 (m, 1H), 4.17 (dd, 1H), 4.07 (app t, 1H), 4.02 (dd, 1H), 3.67 (dd, 1H), 3.14 (m, 4H), 3.09

25


(m, 1H), 2.55 (s, 3H), 2.38 (m, 2H), 2.17 (m, 2H), 1.39 (s, 12H). MS-APCI (m/z): 530.

Example 15 Preparation of 2(*S*)-tert-butoxycarbonylamino-3-methyl-butyrac
 5 (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl ester (12c).



10 Following general procedure F, (*R*)-acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyl
 chloromethyl ester (10) (0.41 g, 0.85 mmol), the cesium salt of *N*-BOC-L-valine (15c) (0.46 g, 1.3 mmol), sodium iodide (0.13 g, 0.85 mmol), and 24 mL of acetonitrile
 gave the title compound in 88% yield (0.49 g). ^1H NMR (400 MHz, CDCl_3): δ 7.45
 15 (dd, 1H), 7.20 (t, 1H), 7.13 (dd, 1H), 5.88 (ABq, 2H), 5.01 (br d, 1H), 4.79 (m, 1H),
 4.17 (m, 2H), 4.06 (t, 1H), 3.99 (dd, 1H), 3.67 (dd, 1H), 3.11 (m, 5H), 2.53 (s, 3H),
 2.36 (m, 2H), 2.12 (m, 3H), 1.38 (s, 9H), 0.95 (d, 3H), 0.87 (d, 3H). MS-APCI
 (m/z): 341, 385, 558, 658.


20 Example 16 Preparation of 2(*R*)-tert-butoxycarbonylamino-3-methyl-butyrac
 (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl ester (12d).



Following general procedure F, (*R*)-acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy-methyl ester (10) (0.9 g, 1.89 mmol), the cesium salt of *N*-BOC-D-valine (15d) (1.02 g, 2.93 mmol), sodium iodide (0.28 g, 1.89 mmol), and 50 mL of acetonitrile gave the title compound in 81% yield (1.00 g). ¹H NMR (400 MHz, CDCl₃): δ 7.48 (dd, 1H), 7.21 (t, 1H), 7.13 (dd, 1H), 5.89 (ABq, 2H), 5.05 (br d, 1H), 4.81 (m, 1H), 4.19 (m, 2H), 4.07 (t, 1H), 4.00 (dd, 1H), 3.67 (dd, 1H), 3.14 (m, 4H), 3.09 (tt, 1H), 2.55 (s, 3H), 2.39 (m, 2H), 2.17 (m, 3H), 1.40 (s, 9H), 0.96 (d, 3H), 0.88 (d, 3H). MS-APCI (*m/z*⁺): 558, 602, 658.

10

Example 17 Preparation of 2(*S*)-tert-butoxycarbonylamino-4-methyl-pentanoic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl ester (12e).




15

Following general procedure F, (*R*)-acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy-methyl ester (10) (0.4 g, 0.84 mmol), the cesium salt of *N*-BOC-L-leucine (15e) (0.47 g, 1.3 mmol), sodium iodide (0.13 g, 0.84 mmol), and 24 mL of acetonitrile gave the title compound in 79% yield (0.45 g). ¹H NMR (400 MHz, CDCl₃): δ 7.44 (dd, 1H), 7.18 (t, 1H), 7.12 (dd, 1H), 5.86 (ABq, 2H), 5.01 (br d, 1H), 4.78 (m, 1H), 4.24 (m, 1H), 4.15 (dd, 1H), 4.06 (t, 1H), 3.98 (dd, 1H), 3.66 (dd, 1H), 3.17-3.03 (m, 5H), 2.51 (s, 3H), 2.34 (m, 2H), 2.14 (m, 2H), 1.66 (m, 1H), 1.53 (m, 2H), 1.36 (s, 9H), 0.89 (d, 6H). MS-APCI (*m/z*⁺): 341, 385, 572, 672.


25

Example 18 Preparation of 2(*S*)-tert-butoxycarbonylamino-3(*S*)-methyl-pentanoic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl ester (12f).



Following general procedure F, (R)-acetyl-{3-[4-(1,1-dioxo-hexahydro-1λ⁶-
 5 thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy-
 chloromethyl ester (10) (0.92 g, 1.9 mmol), the cesium salt of *N*-BOC-L-isoleucine
 (15f) (1.09 g, 3.0 mmol), sodium iodide (0.29, 1.9 mmol), and 50 mL of acetonitrile
 gave the title compound in 71% yield (0.93 g). ¹H NMR (400 MHz, CDCl₃): δ 7.46
 (dd, 1H), 7.21 (t, 1H), 7.14 (dd, 1H), 5.89 (ABq, 2H), 5.00 (br d, 1H), 4.80 (m, 1H),
 10 4.24 (dd, 1H), 4.17 (dd, 1H), 4.07 (app t, 1H), 4.00 (dd, 1H), 3.67 (dd, 1H), 3.13 (m,
 4H), 3.09 (tt, 1H), 2.54 (s, 3H), 2.38 (m, 2H), 2.17 (m, 2H), 1.86 (m, 1H), 1.39 (s,
 9H), 1.39 (m, 1H), 1.16 (m, 1H), 0.92 (d, 3H), 0.88 (t, 3H). MS-APCI (*m/z*):
 341, 385, 572.

15 Example 19 Preparation of 2(*S*)-tert-butoxycarbonylamino-3-phenyl-propionic acid
 (acetyl-{3-[4-(1,1-dioxo-hexahydro-1λ⁶-thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-
 oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl ester (12g).




20

Following general procedure F, (R)-acetyl-{3-[4-(1,1-dioxo-hexahydro-1λ⁶-
 thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy-
 chloromethyl ester (10) (0.75 g, 1.6 mmol), the cesium salt of *N*-BOC-L-
 phenylalanine (15g) (0.96 g, 2.4 mmol), sodium iodide (0.23, 1.6 mmol), and 40 mL

of acetonitrile gave the title compound in 76% yield (0.84 g). ¹H NMR (400 MHz, CDCl₃): δ 7.46 (dd, 1H), 7.23 (m, 4H), 7.13 (m, 3H), 5.87 (ABq, 2H), 5.02 (br d, 1H), 4.79 (m, 1H), 4.56 (m, 1H), 4.14 (dd, 1H), 4.02 (m, 2H), 3.66 (dd, 1H), 3.17-3.00 (m, 7H), 2.54 (s, 3H), 2.38 (m, 2H), 2.17 (m, 2H), 1.36 (s, 9H). MS-APCI (*m/z*⁺): 341, 385, 606.

Example 20 Preparation of pyrrolidine-1,2-dicarboxylic acid 2(*S*)-[(acetyl-{3-[4-(1,1-dioxo-hexahydro-1λ⁶-thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl] ester 1-tert-butyl ester (12h).

10




Following general procedure F, (*R*)-acetyl-{3-[4-(1,1-dioxo-hexahydro-1λ⁶-thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamic acid chloromethyl ester (10) (0.41 g, 0.85 mmol), the cesium salt of *N*-BOC-L-proline (15h) (0.46 g, 1.3 mmol), sodium iodide (0.13 g, 0.85 mmol), and 24 mL of acetonitrile gave the title compound in 87% yield (0.48 g). ¹H NMR (400 MHz, CDCl₃): δ 7.46 (dd, 1H), 7.20 (t, 1H), 7.15 (dd, 1H), 5.88 (s, 2H), 4.83 (m, 1H), 4.30-4.14 (m, 2H), 4.11-3.97 (m, 2H), 3.68 (m, 1H), 3.45 (m, 2H), 3.10 (m, 5H), 2.54 (s, 3H), 2.39 (m, 2H), 2.17 (m, 2H), 1.93 (m, 4H), 1.38 (s, 9H). MS-APCI (*m/z*⁺): 556.

20


Example 21 Preparation of (*R*)-(2-tert-butoxycarbonylamino-acetylamino)-acetic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1λ⁶-thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester (12i).

25



Following general procedure F, (*R*)-acetyl-{3-[4-(1,1-dioxo-hexahydro-1λ⁶-thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamic acid
 5 chloromethyl ester (10) (0.89 g, 1.87 mmol), the cesium salt of *N*-BOC-glycyl-glycine (15i) (1.06g, 2.90 mmol), sodium iodide (0.28 g, 1.87 mmol), and 45 mL of acetonitrile gave the title compound in 82%yield (1.03 g). ¹H NMR (400 MHz, CDCl₃): δ 7.41 (dd, 1H), 7.24 (m, 1H), 7.12 (dd, 1H), 7.00 (br s, 1H), 5.93 (d, 1H), 5.84 (d, 1H), 5.15 (br s, 1H), 4.81 (m, 1H), 4.28 (dd, 1H), 4.11 (m, 4H), 3.84 (app d,
 10 2H), 3.65 (dd, 1H), 3.11 (m, 5H), 2.57 (s, 3H), 2.38 (m, 2H), 2.18 (m, 2H), 1.41 (s, 9H). MS-APCI (*m/z*⁺): 341, 385, 573.


Example 22 Preparation of (*R*)-amino-acetic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1λ⁶-thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-
 15 carbamoyloxy)-methyl ester hydrochloride (13a).



Following General procedure G, except that the entire reaction is performed at
 20 RT. (*R*)-Tert-butoxycarbonylamino-acetic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1λ⁶-thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester (12a) (0.24 g, 0.39 mmol), anisole (0.5 mL), THF (7.3 mL), and 4 M HCl in dioxane (3 mL) gave the title compound in 72% yield (0.16 g). ¹H NMR (400 MHz, DMSO): δ 8.39 (br d, 3H), 7.47 (dd, 1H), 7.39 (t, 1H), 7.28 (dd, 1H), 5.93 (m,
 25 2H), 4.80 (m, 1H), 4.14 (m, 2H), 3.92 (m, 3H), 3.82 (m, 1H), 3.37 (m, 2H), 3.20 (m,


1H), 3.10 (m, 2H), 2.47 (s, 3H), 2.16 (m, 2H), 2.04 (m, 2H). MS-APCI (m/z): 516, 616.

Example 23 Preparation of 2(*S*)-amino-propionic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl ester hydrochloride (13b).




To a mixture of the 2(*S*)-tert-butoxycarbonylamino-propionic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl ester (12b) (0.98 g, 1.56 mmol), anisole (1 mL) and THF (30 mL), is added hydrogen chloride (4 M in dioxane, 11 mL, 46.8 mmol) in a dropwise manner. The mixture is stirred at RT overnight. Under reduced pressure, the mixture is concentrated to one-half of its original volume. Ether is then added dropwise to the mixture while stirring, resulting in the formation of a solid. The solid is collected via filtration, rinsed with ether and ethyl acetate, and dried under vacuum to give the title compound in 38% yield (0.34 g). ¹H NMR (400 MHz, CD₃OD): δ 7.51 (dd, 1H), 7.37 (t, 1H), 7.26 (dd, 1H), 6.02 (ABq, 2H), 4.87 (m, 1H), 4.29 (app q, 1H), 4.19 (m, 2H), 4.10 (dd, 1H), 3.83 (dd, 1H), 3.37 (m, 2H), 3.23 (tt, 1H), 3.12 (m, 2H), 2.54 (s, 3H), 2.35 (m, 2H), 2.18 (m, 2H), 1.59 (d, 3H). MS-APCI (m/z): 530.

Example 24 Preparation of 2(*S*)-tert-butoxycarbonylamino-3-methyl-butyric acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl ester hydrochloride (13c).



Following General procedure G, except that the entire reaction is performed at RT. 2(*S*)-tert-Butoxycarbonylamino-3-methyl-butyrac acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1λ⁶-thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl ester (12c) (0.40 g, 0.61 mmol), anisole (0.6 mL), THF (12 mL), and 4 M HCl in dioxane (4.6 mL) gave the title compound in 55% yield (0.20 g). ¹H NMR (400 MHz, CD₃OD): δ 7.51 (dd, 1H), 7.37 (t, 1H), 7.26 (dd, 1H), 6.06 (d, 1H), 6.01 (d, 1H), 4.87 (m, 1H), 4.20 (m, 2H), 4.10 (m, 2H), 3.84 (dd, 1H), 3.37 (m, 2H), 3.24 (tt, 1H), 3.12 (m, 2H), 2.54 (s, 3H), 2.36 (m, 3H), 2.17 (m, 2H), 1.10 (d, 3H), 1.09 (d, 3H). MS-APCI (*m/z*⁺): 558.

Example 25 Preparation of 2(*R*)-amino-3-methyl-butyrac acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1λ⁶-thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl ester hydrochloride (13d).




Following general procedure G, 2(*R*)-tert-Butoxycarbonylamino-3-methyl-butyrac acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1λ⁶-thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl ester (12d) (0.89 g, 1.35 mmol), anisole (0.12 mL), THF (25 mL), and 4 M HCl in dioxane (10 mL) gave the title compound in 51% yield (0.41 g). ¹H NMR (400 MHz, DMSO): δ 8.52 (br s, 3H), 7.47(dd, 1H), 7.39 (t, 1H), 7.28 (dd, 1H), 5.98 (d, 1H), 5.93 (d, 1H), 4.80 (m, 1H), 4.14 (m, 2H), 4.03 (d, 1H), 3.90 (dd, 1H), 3.82 (dd, 1H), 3.39 (m, 2H), 3.20 (tt, 1H),

3.10 (m, 2H), 2.47 (s, 3H), 2.17 (m, 3H), 2.04 (m, 2H), 0.98 (d, 3H), 0.96 (d, 3H).


MS-APCI (m/z): 558.

Example 26 Preparation of 2(*S*)-amino-4-methyl-pentanoic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl ester hydrochloride (13e).




To a mixture of 2(*S*)-tert-Butoxycarbonylamino-4-methyl-pentanoic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl ester (12e) (0.35 g, 0.52 mmol), anisole (0.5 mL) and THF (10 mL), is added hydrogen chloride (4 M in dioxane, 4 mL, 15.7 mmol) in a dropwise manner. The mixture is stirred at RT overnight. Ether is then added dropwise to the mixture while stirring. Under reduced pressure, the mixture is concentrated to one-third of its original volume. Ether is again added, resulting in the formation of a solid. The solid is collected via filtration, rinsed with ether and ethyl acetate, and dried under vacuum to give the title compound in 39% yield (0.12 g). ^1H NMR (400 MHz, CD_3OD): δ 7.52 (dd, 1H), 7.37 (t, 1H), 7.26 (dd, 1H), 6.02 (ABq, 2H), 4.88 (m, 1H), 4.20 (m, 3H), 4.10 (dd, 1H), 3.83 (m, 1H), 3.35 (m, 2H), 3.23 (tt, 1H), 3.12 (m, 2H), 2.54 (s, 3H), 2.35 (m, 2H), 2.17 (m, 2H), 1.85 (m, 2H), 1.72 (m, 1H), 1.02 (d, 3H), 1.01 (d, 3H). MS-APCI (m/z): 341, 385, 572.

Example 27 Preparation of 2(*S*)-amino-3(*S*)-methyl-pentanoic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl ester hydrochloride (13f).




2(*S*)-tert-Butoxycarbonylamino-3(*S*)-methyl-pentanoic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1λ⁶-thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl ester (12f) (0.82 g, 1.23 mmol), anisole (0.2 mL) and THF (25 mL) are cooled to 0 °C. Hydrogen chloride (4 M in dioxane, 9 mL, 36.8 mmol) is added in a dropwise manner. After complete addition, the ice-bath is removed and the mixture is stirred at RT overnight. Under reduced pressure, the mixture is concentrated to one-third of its original volume. Ether is then added dropwise to the mixture while stirring, resulting in the formation of a solid. The solid is collected via filtration, rinsed with ether, and dried under vacuum to give the title compound in 52% yield (0.39 g). ¹H NMR (400 MHz, CD₃OD): δ 7.51 (d, 1H), 7.36 (t, 1H), 7.26 (d, 1H), 6.05 (d, 1H), 6.00(d, 1H), 4.87 (m, 1H), 4.20 (m, 3H), 4.09 (dd, 1H), 3.84 (dd, 1H), 3.37 (m, 2H), 3.23 (tt, 1H), 3.11 (m, 2H), 2.54 (s, 3H), 2.34 (m, 2H), 2.17 (m, 2H), 2.06 (m, 1H), 1.56 (m, 1H), 1.39 (m, 1H), 1.06 (d, 3H), 1.00 (t, 3H). MS-APCI (*m/z*⁺): 341, 385, 572.

Example 28 Preparation of 2(*S*)-amino-3-phenyl-propionic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1λ⁶-thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl ester hydrochloride (13g).




- 2(S)-tert-Butoxycarbonylamino-3-phenyl-propionic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(R)-ylmethyl}-carbamoyloxy)-methyl ester (12g) (0.78 g, 1.1 mmol), anisole (0.5 mL) and THF (20 mL) are cooled to 0 °C. Hydrogen chloride (4 M in dioxane, 8 mL, 33.1 mmol) is added in a dropwise manner. After complete addition, the ice-bath is removed and the mixture is stirred at RT overnight. Under reduced pressure, the mixture is concentrated to one-half of its original volume. Ether is then added dropwise to the mixture while stirring, resulting in the formation of a solid. The solid is collected via filtration, rinsed with ether and ethyl acetate, and dried under vacuum to give the title compound in 63% yield (0.45 g). ¹H NMR (400 MHz, CD₃OD): δ 7.50 (dd, 1H), 7.39-7.24 (m, 7H), 6.02 (d, 1H), 5.97 (d, 1H), 4.86 (m, 1H), 4.50 (dd, 1H), 4.18 (m, 2H), 4.09 (dd, 1H), 3.83 (dd, 1H), 3.35 (m, 3H), 3.21 (m, 2H), 3.11 (m, 2H), 2.53 (s, 3H), 2.34 (m, 2H), 2.16 (m, 2H). MS-APCI (*m/z*⁺): 341, 385, 606.
- Example 29 Preparation of pyrrolidine-2(S)-carboxylic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(R)-ylmethyl}-carbamoyloxy)-methyl ester hydrochloride (13h).



20

- To a mixture of pyrrolidine-1,2-dicarboxylic acid 2(S)-[(acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(R)-ylmethyl}-carbamoyloxy)-methyl] ester 1-tert-butyl ester (12h) (0.43 g, 0.66 mmol), anisole (0.6 mL) and THF (14 mL), is added hydrogen chloride (4 M in dioxane, 5 mL, 19.9 mmol) in a dropwise manner. The mixture is stirred at RT overnight. Under reduced pressure, the mixture is concentrated to one-third of its original volume. Ether is added dropwise while stirring, resulting in the formation of a solid. The solid is collected via filtration, rinsed with ether and ethyl acetate, and dried under vacuum to give the title compound in 94% yield (0.37 g). MS-APCI (*m/z*⁺): 341, 385.

Example 30 Preparation of (*R*)-(2-amino-acetylamino)-acetic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester hydrochloride (13i).




5

Following general procedure G, (*R*)-(2-tert-Butoxycarbonylamino-acetylamino)-acetic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester (12i) (0.48 g, 0.71 mmol), anisole (0.1 mL), THF (14 mL), and 4 M HCl in dioxane (5 mL) gave the title compound in 66% yield (0.29 g). ¹H NMR (400 MHz, CD₃OD): δ 7.51 (dd, 1H), 7.36 (t, 1H), 7.26 (dd, 1H), 5.95 (d, 1H), 5.91 (d, 1H), 4.87 (m, 1H), 4.20 (m, 4H), 4.05 (m, 1H), 3.82 (dd, 1H), 3.77 (m, 2H), 3.37 (m, 2H), 3.23 (tt, 1H), 3.12 (m, 2H), 2.53 (s, 3H), 2.35 (m, 2H), 2.18 (m, 2H). MS-APCI (*m/z* +): 341, 385, 573.

15

Example 31 Preparation of acetic acid 1-(acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-ethyl ester (16).




20

Acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamic acid 1(*R,S*)-chloro-ethyl ester (11) (0.49 g, 1 mmol), mercury(II) acetate (0.37 g, 1.175 mmol), and acetic acid (6.3 mL, 109 mmol) are stirred at RT overnight. Ether and water are added and the layers are separated. The organic layer is washed several times with water, brine, dried over Na₂SO₄ and

25

conc *in vacuo*. After purification by silica gel chromatography, the product is re-dissolved in CH₂Cl₂ and washed with several portions of sat NaHCO₃, water, dried over Na₂SO₄ and conc *in vacuo* to give the title compound in 43% yield (0.51 g) as a mixture of two diastereomers in a 1:1 ratio. ¹H NMR (400 MHz, CDCl₃): δ 7.46 (dt, 1H), 7.21 (m, 1H), 7.13 (m, 1H), 6.88 (q, 1H), 4.82 (m, 0.5H), 4.75 (m, 0.5H), 4.13 (m, 1H), 4.04 (m, 2H), 3.73 (dd, 0.5H), 3.67 (dd, 0.5H), 3.12 (m, 5H), 2.55 (s, 1.5H), 2.53 (s, 1.5H), 2.38 (m, 2H), 2.17 (m, 2H), 2.13 (s, 1.5H), 2.06 (s, 1.5H), 1.57 (d, 1.5H), 1.54 (d, 1.5H). MS-APCI (*m/z*): 341, 385, 427, 515.

- 10 Example 32 Preparation of (*R*)-piperidine-1,4-dicarboxylic acid 4-[(acetyl-{3-[4-(1,1-dioxo-hexahydro-1λ⁶-thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl] ester 1-tert-butyl ester (17).




15

- To (*R*)-acetyl-{3-[4-(1,1-dioxo-hexahydro-1λ⁶-thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyl ester (10) (751.8 mg, 1.58 mmol) and sodium iodide (236.0 mg, 1.58 mmol) in acetonitrile (30 mL), is added the cesium salt of *N*-BOC-isonipecotic acid (884.2 mg, 2.45 mmol). The mixture is heated to reflux overnight. After cooling to RT, the mixture is filtered and washed with dichloromethane. The filtrate is diluted with CH₂Cl₂ and water and the layers are separated. The aq layer is extracted with dichloromethane twice and the combined organic layers are washed with water, brine, dried over sodium sulfate and conc *in vacuo*. Purification by silica gel chromatography gave the title compound in 72% yield (757.3 mg, 1.13 mmol). ¹H NMR (400 MHz, CDCl₃): δ 7.47 (dd, 1H), 7.24 (t, 1H), 7.14 (dd, 1H), 5.88 (s, 2H), 4.78-4.85 (m, 1H), 4.18 (dd, 1H), 4.08 (t, 2H), 4.03 (dd, 2H), 3.67 (dd, 1H), 3.13-3.20 (m, 4H), 3.10 (dt, 1H), 2.83 (t, 2H), 2.60 (tt, 1H), 2.59 (s, 3H), 2.35-2.46 (m, 2H), 2.17-2.23 (m, 2H), 1.90-1.96 (m, 2H), 1.57-1.686 (m, 2H) 1.45 (s, 9H). MS-APCI (*m/z*): 570.
- 25


Example 33 Preparation of (*R*)-piperidine-4-carboxylic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester hydrochloride (18).

5



(*R*)-Piperidine-1,4-dicarboxylic acid 4-[(acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl] ester 1-tert-butyl ester (17) (588.5 mg, 0.88 mmol) and anisole (0.9 mL) are
 10 diluted with tetrahydrofuran (17 mL). Hydrochloric acid in dioxane (4 M, 6.6 mL) is added dropwise and the resultant mixture is stirred at RT overnight. Ether is added dropwise to the mixture while stirring, resulting in the formation of a solid. The solid is collected via filtration, rinsed with ether, and dried under vacuum to give the title compound in quantitative yield (530.8 mg, 0.88 mmol) ¹H NMR (400 MHz, CD₃OD): δ 7.51 (dd, 1H), 7.36 (t, 1H), 7.26 (dd, 1H), 5.92 (s, 2H), 4.15-4.22 (m, 2H),
 15 4.05 (dd, 1H), 3.81 (dd, 1H), 3.36-3.43 (m, 4H), 3.23 (tt, 1H), 3.05-3.14 (m, 5H), 2.90 (tt, 1H), 2.52 (s, 3H), 2.35 (q, 2H), 2.13-2.26 (m, 4H), 1.92-2.00 (m, 2H). MS-APCI (*m/z*⁺): 570.

20 Example 34 Preparation of 2(*R*)-phenyl-propionic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl ester (19).




25

(*R*)-acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamic acid chloromethyl ester (10) (0.40g, 0.84 mmol), cesium 2(*R*)-phenyl-propionate (0.37g, 1.31 mmol) and sodium iodide (0.13g, 0.86 mmol) in acetonitrile (25 mL) are heated to reflux overnight. After cooling to
 5 RT, water is added and the reaction mixture is extracted with EtOAc and then with dichloromethane. The organic phases are washed separately with brine and then the organic layers are combined, dried over MgSO₄, filtered, and conc *in vacuo*. The isolated residue is subjected to silica gel flash chromatography, eluting with MeOH/CH₂Cl₂ gradient (0-5% MeOH over 1 hour and 20 minutes) to afford the title
 10 compound. Isolated yield: 81%. ¹H NMR (400 MHz, DMSO-*d*₆): δ 7.43-7.38 (m, 1H), 7.33 (t, 1H), 7.27-7.15 (m, 6H), 5.78-5.72 (m, 2H), 4.63-4.57 (m, 1H), 4.04-3.95 (m, 2H), 3.84 (q, 1H), 3.76-3.69 (m, 2H), 3.36-3.26 (m, partially obscured by water, 2H), 3.17-3.12 (m, 1H), 3.07-3.04 (m, 2H), 2.31 (d, 3H), 2.11 (q, 2H), 2.01-1.97 (m, 2H), 1.35 (d, 3H); MS-APCI (*m/z*⁺): 341, 385, 517, 591.

15

Example 35 Preparation of 2(*S*)-phenyl-propionic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl ester (20)




20

(*R*)-acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamic acid chloromethyl ester (10) (0.40g, 0.84 mmol), cesium 2(*S*)-phenyl-propionate (0.37g, 1.31 mmol) and sodium iodide (0.13g, 0.86 mmol) in acetonitrile (25 mL) are heated to reflux overnight. After cooling to
 25 RT, water is added and the reaction mixture is extracted with EtOAc and then with dichloromethane. The organic phases are washed separately with brine and then the organic layers are combined, dried over MgSO₄, filtered, and conc *in vacuo*. The isolated residue is subjected to silica gel flash chromatography, eluting with


MeOH/CH₂Cl₂ gradient (0-5% MeOH over 1 hour and 20 minutes) to afford the title compound. Isolated yield: 75%. ¹H NMR (400 MHz, DMSO-*d*₆): δ 7.43-7.39 (m, 1H), 7.33(t, 1H), 7.27-7.15 (m, 6H), 5.78-5.72 (m, 2H), 4.63-4.57 (m, 1H), 4.02-3.95 (m, 2H), 3.84 (q, 1H), 3.76-3.69 (m, 2H), 3.36-3.26 (m, partially obscured by water, 2H), 3.18-3.12 (m, 1H), 3.07-3.04 (m, 2H), 2.30 (d, 3H), 2.11 (q, 2H), 2.01-1.97 (m, 2H), 1.35 (d, 3H); MS-APCI (*m/z*⁺): 341, 385, 517, 591.

Example 36 Preparation of isonicotinic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1λ⁶-thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl ester (21)



(*R*)-acetyl-{3-[4-(1,1-dioxo-hexahydro-1λ⁶-thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy-methyl ester (21) (0.40g, 0.84 mmol), cesium isonicotinate (0.33g, 1.301 mmol) and sodium iodide (0.13g, 0.86 mmol) in acetonitrile (25 mL) are heated to reflux overnight. After cooling to RT, water is added and the reaction mixture is extracted with EtOAc and then with dichloromethane. The organic phases are washed separately with brine and then the organic layers are combined, dried over MgSO₄, filtered, and conc *in vacuo*. The isolated residue is subjected to silica gel flash chromatography, eluting with MeOH/CH₂Cl₂ gradient (0-5% MeOH over 1 hour and 20 minutes) to afford the title compound. Isolated yield: 80%. ¹H NMR (400 MHz, DMSO-*d*₆): δ 8.78 (d, 2H), 7.82 (d, 2H), 7.36 (d, 1H), 7.30 (t, 1H), 7.18 (d, 1H), 6.02 (dd, 2H), 4.76-4.70 (m, 1H), 4.10-4.05 (m, 2H), 3.89-3.85 (m, 1H), 3.77-3.74 (m, 1H), 3.35-3.26 (m, partially obscured by water, 2H), 3.19-3.11 (m, 1H), 3.07-3.04 (m, 2H), 2.43 (d, partially obscured by DMSO, 3H), 2.11 (q, 2H), 2.01-1.97 (m, 2H); MS-APCI (*m/z*⁺): 341, 564.

Example 37 Preparation of propionic acid 1-(acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(R)-ylmethyl}-carbamoyloxy)-ethyl ester (22)




5

Acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(R)-ylmethyl}-carbamoyloxy)-ethyl ester (11) (0.20g, 0.41 mmol) and sodium iodide (0.061g, 0.41 mmol) are placed in acetonitrile (25 mL) and stirred at RT overnight. Cesium propionate (0.17g, 0.82 mmol) is then added and the reaction is heated at reflux overnight. After cooling to RT, water is added and the reaction mixture is extracted with EtOAc and then with dichloromethane. The organic phases are washed separately with brine and then the organic layers are combined, dried over MgSO₄, filtered, and conc *in vacuo*. The isolated residue is subjected to silica gel flash chromatography, eluting with MeOH/CH₂Cl₂ gradient (0-5% MeOH over 1 hour and 20 minutes) to afford the title compound. Isolated yield: 67%. ¹H NMR (400 MHz, CDCl₃): δ 7.48-7.42 (m, 1H), 7.21-7.17 (m, 1H), 7.13-7.10 (m, 1H), 6.90-6.85 (m, 1H), 4.83-4.69 (m, 1H), 4.14-3.98 (m, 3H), 3.73-3.64 (m, 1H), 3.13-3.04 (m, 5H), 2.52 (d, 3H), 2.48-2.31 (m, 3H), 2.29-2.13 (m, 2H), 1.56-1.51 (m, 4H), 1.15-1.07 (m, 3H).

20


Example 38 Preparation of isonicotinic acid 1-(acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(R)-ylmethyl}-carbamoyloxy)-ethyl ester (23)



25

Acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamic acid 1-chloro-ethyl ester (11) (0.40g, 0.81 mmol) and cesium isonicotinate (0.42g, 1.64 mmol) in acetonitrile (20 mL) are heated to reflux overnight. After cooling to RT, water is added and the reaction mixture is extracted with EtOAc and then with dichloromethane. The organic phases are washed separately with brine and then the organic layers are combined, dried over MgSO₄, filtered, and conc *in vacuo*. The isolated residue is subjected to silica gel flash chromatography, eluting with MeOH/CH₂Cl₂ gradient (0-5% MeOH over 1 hour and 20 minutes) to afford the title compound. Isolated yield: 83%. ¹H NMR (400 MHz, DMSO-*d*₆): δ 8.78-8.74 (m, 2H), 7.85 (dd, 1H), 7.79 (dd, 1H), 7.40-7.35 (m, 1H), 7.31 (t, 1H), 7.21-7.17 (m, 1H), 7.01-6.94 (m, 1H), 4.79-4.72 (m, 1H), 4.12-4.00 (m, 2H), 3.91-3.84 (m, 1H), 3.78-3.73 (m, 1H), 3.36-3.26 (m, partially obscured by water, 2H), 3.17-3.11 (m, 1H), 3.07-3.03 (m, 2H), 2.40 (d, 3H), 2.15-2.04 (m, 2H), 2.00-1.97 (m, 2H) 1.59 (dd, 3H).


Example 39 Preparation of 2(*S*)-tert-butoxycarbonylamino-3(*S*)-methyl-pentanoic acid 1-(acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-ethyl ester (12j).



Acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamic acid 1-chloro-ethyl ester (11) (1.00g, 2.04 mmol), the cesium salt of *N*-BOC-L-isoleucine (15f) (1.48g, 4.07 mmol), sodium iodide (0.31g, 2.07 mmol) and acetonitrile (50 mL) are heated to reflux overnight. After cooling to RT, water is added and the reaction mixture is extracted with EtOAc and then with dichloromethane. The organic phases are washed separately with brine and then the organic layers are combined, dried over MgSO₄, filtered, and conc *in vacuo*. The isolated residue is subjected to silica gel flash chromatography, eluting


with MeOH/CH₂Cl₂ gradient (0-4% MeOH over 1 hour and 30 minutes) to afford the title compound. Isolated yield: 79%. ¹H NMR (400 MHz, CDCl₃): δ 7.48-7.42 (m, 1H), 7.22-7.17 (m, 1H), 7.14-7.10 (m, 1H), 6.91-6.85 (m, 1H), 5.08 (d, 0.5H), 4.94 (d, 0.5H), 4.81-4.74 (m, 1H), 4.24-3.98 (m, 4H), 3.71-3.64 (m, 1H), 3.13-3.04 (m, 5H), 2.51 (d, 3H), 2.42-2.31 (m, 2H), 2.17-2.13 (m, 2H), 1.84-1.81 (br m, 1H), 1.57 (dd, 3H), 1.52 (s, 1H), 1.38 (d, 9H), 1.21-1.09 (m, 1H), 0.93-0.85 (m, 6H); MS-APCI (*m/z*⁺): 341, 385, 586, 686.

Example 40 Preparation of 2,2-dimethyl-propionic acid 1-(acetyl-{3-[4-(1,1-dioxo-hexahydro-1λ⁶-thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-ethyl ester (24).




Acetyl-{3-[4-(1,1-dioxo-hexahydro-1λ⁶-thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-ethyl ester (11) (0.40g, 0.81 mmol), cesium 2,2-dimethyl-propionate (0.38g, 1.63 mmol), sodium iodide (0.121g, 0.81 mmol) and acetonitrile (25 mL) are heated to reflux overnight. After cooling to RT, water is added and the reaction mixture is extracted with EtOAc and then with dichloromethane. The organic phases are washed separately with brine and then the organic layers are combined, dried over MgSO₄, filtered, and conc *in vacuo*. The isolated residue is subjected to silica gel flash chromatography, eluting with MeOH/CH₂Cl₂ gradient (0-4% MeOH over 1 hour and 30 minutes) to afford the title compound. Isolated yield: 30%. ¹H NMR (400 MHz, DMSO-*d*₆): δ 7.41-7.38 (m, 1H), 7.33 (t, 1H), 7.22 (dd, 1H), 6.71-6.65 (m, 1H), 4.77-4.68 (m, 1H), 4.12-3.94 (m, 2H), 3.88-3.74 (m, 2H), 3.36-3.28 (m, 2H), 3.18-3.12 (m, 1H), 3.07-3.03 (m, 2H), 2.37 (d, 3H), 2.15-2.06 (m, 2H), 2.00-1.97 (m, 2H) 1.44 (dd, 3H); 1.08 (d, 9H).

Example 41 Preparation of 2(*S*)-Amino-3(*S*)-methyl-pentanoic acid 1-(acetyl-{3-[4-(1,1-dioxo-hexahydro-1λ⁶-thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-ethyl ester hydrochloride (13j).



2(S)-tert-butoxycarbonylamino-3(S)-methyl-pentanoic acid 1-(acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(R)-ylmethyl}-carbamoyloxy)-ethyl ester (12j) (1.00g, 1.46 mmol), anisole (0.24g, 2.188 mmol) and THF (30 mL) are cooled in an ice bath. Hydrochloric acid (4 N in dioxane, 10.94 mL) is added dropwise. The solution is stirred in an ice bath for 30 min and then at RT for 4 h. The reaction mixture is re-cooled to 0°C and ethyl ether is added. The resulting solids are collected by filtration and washed with a cold ethyl ether/ethyl acetate mixture to afford the title compound. Isolated yield: 64%. ¹H NMR (400 MHz, DMSO-*d*₆): δ 8.46 (br s, 3H), 7.43-7.39 (m, 1H), 7.36 (t, 1H), 7.22 (d, 1H), 6.85-6.79 (m, 1H), 4.77-4.71 (m, 1H), 4.13-4.00 (m, 2H), 3.96 (dd, 1H), 3.88-3.84 (m, 1H), 3.80-3.74 (m, 1H), 3.51-3.28 (m, partially obscured by water, 2H), 3.18-3.12 (m, 1H), 3.04 (d, 2H), 2.40 (d, 3H), 2.08 (q, 2H), 1.97-1.93 (m, 2H), 1.90-1.84 (br m, 1H), 1.50 (dd, 3H), 1.44-1.36 (m, 1H), 1.26-1.14 (m, 1H), 0.88 (dd, 3H), 0.84-0.79 (m, 3H).

Example 42 Preparation of Cyclopentanecarboxylic acid 1-(acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(R)-ylmethyl}-carbamoyloxy)-ethyl ester (25).




Acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(R)-ylmethyl}-carbamoyloxy)-ethyl ester (11) (0.20g, 0.41 mmol), cesium cyclopentanecarboxylate (0.20g, 0.81 mmol) and sodium iodide

(0.061g, 0.41 mmol) in acetonitrile (15 mL) were heated to reflux overnight. Upon cooling to RT, water was added and the reaction mixture was extracted with ethyl acetate and then with dichloromethane. The organic phases were washed with brine, combined, dried over magnesium sulfate, filtered, and conc *in vacuo*. The isolated
5 residue was subjected to silica gel flash chromatography, eluting with MeOH/CH₂Cl₂ gradient (0-4% MeOH over 1 hour and 20 minutes) to afford the title compound.
Isolated yield: 63%. ¹H NMR (400 MHz, DMSO-*d*₆): δ 7.39 (dd, 1H), 7.35-7.31 (m, 1H), 7.24-7.20 (m, 1H), 6.73-6.69 (m, 1H), 4.74-4.70 (m, 1H), 4.12-3.93 (m, 2H), 3.88-3.73 (m, 2H), 3.39-3.28 (m, 2H), 3.26 (s, 3H), 3.18-3.11 (m, 1H), 3.06-3.03 (m,
10 2H), 2.76-2.68 (m, 1H), 2.37 (d, 3H), 2.15-2.06 (m, 2H), 2.00-1.97-(m, 2H), 1.80-1.70 (m, 2H), 1.68-1.56 (m, 2H), 1.54-1.43 (m + dd, 4H).

CLAIMS

We claim:

1. A compound of formula I



I

or a pharmaceutically acceptable salt thereof wherein:

X is -SO-, -SO₂-, or -SONR⁶-;

Z is -C-, -CH-, or -N-;

- 10 each "....." is independently absent, or a bond;

each W is independently -CHR⁶-, -CHR⁶CH₂-, or absent;

R¹ is

- (a) -NH₂,
- (b) -NHC₁₋₄alkyl,
- 15 (c) -C₁₋₆alkyl, optionally substituted with 1-3 halo,
- (d) -C₂₋₆alkenyl,
- (e) -(CH₂)_nC(=O)C₁₋₄alkyl,
- (f) -OC₁₋₄alkyl,
- (g) -SC₁₋₄alkyl, or
- 20 (h) -(CH₂)_nC₃₋₇cycloalkyl;

R² and R³ are independently -H, or -F;

R⁴ is -H, -C₁₋₄alkyl, or -CO₂R⁶;


R⁵ is

- (a) -C₁₋₁₀alkyl,
- 25 (b) -C₃₋₇cycloalkyl,
- (c) -aryl,
- (d) -het,
- (e) -OC₁₋₁₀alkyl,
- (f) -O-C₃₋₇cycloalkyl,
- 30 (g) -O-aryl,
- (h) -O-het,

- (i) $-C(R^6)(R^7)NH_2$,
 - (j) $-C(R^6)(R^7)NHCO_2C_{1-4}alkyl$,
 - (k) $-C(R^6)(R^7)NHCOC(R^6)(R^7)NH_2$, or
 - (l) $-C(R^6)(R^7)NHCOC(R^6)(R^7)NHCO_2C_{1-4}alkyl$;
- 5 each R^6 is independently -H, or $-C_{1-4}alkyl$;
 each R^7 is independently -H, $-C_{1-4}alkyl$ wherein $-C_{1-4}alkyl$ is optionally substituted with OR^6 , SR^6 , CO_2R^6 , $CONH_2$, NH_2 , $NHC(=NH)NH_2$, phenyl, het, or R^6 and R^7 taken together form het;
 aryl is phenyl, biphenyl, or naphthyl;
- 10 het is an aromatic ring, or a saturated or unsaturated ring that is not aromatic, of 3 to 10 carbon atoms and 1 to 4 heteroatoms selected from the group consisting of O, NQ, and S within the ring, wherein Q is absent, H, $C_{1-4}alkyl$ or $-CO_2C_{1-4}alkyl$;
 at each occurrence, $C_{1-10}alkyl$ is optionally substituted with 1-3 halo, OH, CN, NO_2 , $OC_{1-4}alkyl$, NR^6R^6 , $C(=O)C_{1-4}alkyl$, $OC(=O)C_{1-4}alkyl$, $C(=O)OC_{1-4}alkyl$, phenyl or $S(O)_nC_{1-4}alkyl$;
- 15 at each occurrence, $C_{3-7}cycloalkyl$ is optionally substituted with 1-3 halo, OH, CN, NO_2 , $C_{1-4}alkyl$, $OC_{1-4}alkyl$, NR^6R^6 , $C(=O)C_{1-4}alkyl$, $OC(=O)C_{1-4}alkyl$, $C(=O)OC_{1-4}alkyl$, or $S(O)_nC_{1-4}alkyl$;
- at each occurrence, aryl is optionally substituted with 1-3 halo, OH, CN, NO_2 , $C_{1-4}alkyl$, $OC_{1-4}alkyl$, NR^6R^6 , $C(=O)C_{1-4}alkyl$, $OC(=O)C_{1-4}alkyl$, $C(=O)OC_{1-4}alkyl$, or $S(O)_nC_{1-4}alkyl$;
- 20 at each occurrence het is optionally substituted with 1-3 halo, OH, CN, NO_2 , $C_{1-4}alkyl$, $OC_{1-4}alkyl$, NR^6R^6 , $C(=O)C_{1-4}alkyl$, $OC(=O)C_{1-4}alkyl$, $C(=O)OC_{1-4}alkyl$, or $S(O)_nC_{1-4}alkyl$, or oxo;
- 25 and each n is independently 0-4.
2. A compound of claim 1 wherein each W is independently $-CH_2-$.
3. A compound of claim 1 wherein X is $-SO_2-$.

4. A compound of claim 1 wherein Z is -CH-.
5. A compound of claim 1 wherein Z is -N-.
- 5 6. A compound of claim 1 wherein R² is H and R³ is F.
7. A compound of claim 1 wherein R¹ is C₁₋₄alkyl, optionally substituted with one, two, or three halo.
- 10 8. A compound of claim 1 wherein R¹ is -CH₃.
9. A compound of claim 1 wherein R¹ is -CH₂CH₃, -CHF₂, -CF₃, or -CHCl₂.
- 15 10. A compound of claim 1 wherein R⁴ is -H., or -CH₃.
11. A compound of claim 1 wherein R⁵ is -C₁₋₅alkyl, optionally substituted with phenyl.
- 20 12. A compound of claim 1 wherein R⁵ is cyclopropane, cyclopentane, or cyclohexane.
13. A compound of claim 1 wherein R⁵ is phenyl.
- 25 14. A compound of claim 1 wherein R⁵ is an unsaturated het of 3 to 4 carbon atoms and 1 to 2 heteroatoms selected from the group consisting of O, NQ, and S within the ring, wherein Q is absent, H, C₁₋₄ alkyl or -CO₂C₁₋₄alkyl.
- 30 15. A compound of claim 14 wherein R⁵ is tetrahydro-pyran, piperidine, or pyrrolidine.

16. A compound of claim 1 wherein R^5 is $C(R^6)(R^7)NH_2$ wherein R^6 is H or methyl; and R^7 is H, Me, Et, iso-propyl, sec-butyl, $CH(Me)Et$, benzyl, CH_2OH , CH_2COOH , CH_2CH_2COOH , $CONH_2$, or CH_2CONH_2 .
17. A compound of claim 1 wherein R^5 is $C(R^6)(R^7)NH_2$ wherein R^6 is H; and R^7 is C_{1-5} alkyl optionally substituted with phenyl.
18. A compound of claim 1 wherein R^5 is $C(R^6)(R^7)NH_2$ wherein R^6 is H; and R^7 is C_{1-4} alkyl.
19. A compound of claim 1 wherein R^5 is $C(R^6)(R^7)NHCOC(R^6)(R^7)NH_2$ wherein R^6 is H or methyl; and R^7 is H, Me, Et, iso-propyl, sec-butyl, $CH(Me)Et$, benzyl, CH_2OH , CH_2COOH , CH_2CH_2COOH , $CONH_2$, or CH_2CONH_2 .
20. A compound of claim 1 which is a compound of formula Ia




Ia

- wherein R^1 is $-C_{1-6}$ alkyl, optionally substituted with 1-3 halo,
- R^2 and R^3 are independently $-H$, or $-F$;
- R^4 is $-H$, or $-C_{1-4}$ alkyl;
- R^5 is
- (a) $-C_{1-10}$ alkyl,
 - (b) $-C_{3-7}$ cycloalkyl,
 - (c) $-phenyl$,
 - (d) $-het$,
 - (e) $-C(R^6)(R^7)NH_2$,
 - (f) $-C(R^6)(R^7)NHCO_2C_{1-4}$ alkyl,
 - (g) $-C(R^6)(R^7)NHCOC(R^6)(R^7)NH_2$, or
 - (h) $-C(R^6)(R^7)NHCOC(R^6)(R^7)NHCO_2C_{1-4}$ alkyl;
- each R^6 is independently $-H$, or $-C_{1-4}$ alkyl; and


each R^7 is independently -H, $-C_{1-4}$ alkyl wherein $-C_{1-4}$ alkyl is optionally substituted with OR^6 , SR^6 , CO_2R^6 , $CONH_2$, NH_2 , $NHC(=NH)NH_2$, phenyl, het, or R^6 and R^7 taken together form het.

- 5 21. A compound of claim 1 which is a compound of formula Ib



Ib.

- 10 22. A compound of claim 1 which is a compound of formula Ic



Ic

wherein W is $-CH_2-$, or $-CH_2CH_2-$.

- 15 23. A compound of claim 1 wherein pharmaceutically acceptable salt is hydrogen chloride.

24. A compound of claim 1 which is

- (1) ([acetyl((5R)-3-[4-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl)-methyl)amino] carbonyl)oxy)methylacetate,
 20 (2) (R)- propionic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoxyloxy)-methyl ester,
 (3) (R)- isobutyric acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoxyloxy)-methyl ester,
 25 (4) (R)- 3-methyl-butyric acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoxyloxy)-methyl ester,
 (5) (R)- butyric acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoxyloxy)-methyl ester,

- (6) (R)- 2.2-dimethy-propionic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester,
- (7) (R)- 3.3-dimethy-butyric acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester,
- 5 (8) (R)-cyclopropanecarboxylic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester,
- (9) (R)-cyclopentanecarboxylic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester,
- 10 (10) (R)-cyclohexanecarboxylic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester,
- (11) (R)-benzoic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester,
- (12) (R)-tetrahydro-pyran-4-carboxylic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester,
- 20 (13) (R)-tert-butoxycarbonylamino-acetic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester,
- (14) 2(S)-tert-butoxycarbonylamino-propionic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(R)-ylmethyl}-carbamoyloxy)-methyl ester,
- 25 (15) 2(S)-tert-butoxycarbonylamino-3-methyl-butyric acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(R)-ylmethyl}-carbamoyloxy)-methyl ester,
- (16) 2(R)-tert-butoxycarbonylamino-3-methyl-butyric acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(R)-ylmethyl}-carbamoyloxy)-methyl ester,
- 30

- (17) 2(*S*)-tert-butoxycarbonylamino-4-methyl-pentanoic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl ester,
- (18) 2(*S*)-tert-butoxycarbonylamino-3(*S*)-methyl-pentanoic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl ester,
- (19) 2(*S*)-tert-butoxycarbonylamino-3-phenyl-propionic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl ester,
- (21) Pyrrolidine-1,2-dicarboxylic acid 2(*S*)-[(acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl] ester 1-tert-butyl ester,
- (21) (*R*)-(2-tert-butoxycarbonylamino-acetyl-amino)-acetic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester,
- (22) (*R*)-amino-acetic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoyloxy)-methyl ester hydrochloride,
- (23) 2(*S*)-amino-propionic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl ester hydrochloride,
- (24) 2(*S*)-tert-butoxycarbonylamino-3-methyl-butyric acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl ester hydrochloride,
- (25) 2(*R*)-amino-3-methyl-butyric acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl ester hydrochloride,
- (26) 2(*S*)-amino-4-methyl-pentanoic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl ester hydrochloride,
- (27) 2(*S*)-amino-3(*S*)-methyl-pentanoic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl ester hydrochloride,.

- (28) 2(*S*)-amino-3-phenyl-propionic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoxyloxy)-methyl ester hydrochloride,
- (29) Pyrrolidine-2(*S*)-carboxylic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoxyloxy)-methyl ester hydrochloride,
- (30) (*R*)-(2-amino-acetyl-amino)-acetic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoxyloxy)-methyl ester hydrochloride,
- (31) Acetic acid 1-(acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoxyloxy)-ethyl ester,
- (32) (*R*)-piperidine-1,4-dicarboxylic acid 4-[(acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoxyloxy)-methyl] ester 1-tert-butyl ester,
- (33) (*R*)-piperidine-4-carboxylic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamoxyloxy)-methyl ester hydrochloride,
- (34) 2(*R*)-phenyl-propionic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoxyloxy)-methyl ester,
- (35) 2(*S*)-phenyl-propionic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoxyloxy)-methyl ester,
- (36) Isonicotinic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoxyloxy)-methyl ester,
- (37) Propionic acid 1-(acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoxyloxy)-ethyl ester,
- (38) Isonicotinic acid 1-(acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoxyloxy)-ethyl ester,
- (39) 2(*S*)-tert-butoxycarbonylamino-3(*S*)-methyl-pentanoic acid 1-(acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoxyloxy)-ethyl ester,

- (40) 2,2-dimethyl-propionic acid 1-(acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(R)-ylmethyl}-carbamoyloxy)-ethyl ester,
- (41) Preparation of 2(*S*)-Amino-3(*S*)-methyl-pentanoic acid 1-(acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-ethyl ester hydrochloride, or
- (42) Cyclopentanecarboxylic acid 1-(acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-ethyl ester.
- 10
25. A compound of claim 1 which is
- (1) 2(*S*)-amino-3(*S*)-methyl-pentanoic acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl ester hydrochloride,
- 15 (2) 2(*R*)-amino-3-methyl-butyric acid (acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-carbamoyloxy)-methyl ester hydrochloride, or
- (3) 2(*S*)-Amino-3(*S*)-methyl-pentanoic acid 1-(acetyl-{3-[4-(1,1-dioxo-hexahydro-1 λ^6 -thiopyran-4-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(*R*)-ylmethyl}-
- 20 carbamoyloxy)-ethyl ester hydrochloride.
26. A pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- 25 27. A method for treating bacteria infections comprising administering to a mammal being treated a pharmaceutically effective amount of the compound of claim 1.
28. The method of claim 27 wherein the compound of claim 1 is administered
- 30 parenterally, topically, rectally, or intranasally.

29. The method of claim 27 wherein said compound is administered in an amount of from about 0.1 to about 100 mg/kg of body weight/day.

30. The method of claim 27 wherein said compound is administered in an amount
5 of from about 1 to about 50 mg/kg of body weight/day.

INTERNATIONAL SEARCH REPORT

PCT/IB2004/002983

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D413/10 C07D413/14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	WO 2004/002967 A (GORDEEV MIKHAIL F ; HESTER JACKSON B JR (US); STEVENS JEFFREY C (US);) 8 January 2004 (2004-01-08) claims 1-44	1-30
Y	WO 03/062231 A (GORDEEV MIKHAIL F ; RENSLO ADAM (US); UPJOHN CO (US); LAM STUART (US);) 31 July 2003 (2003-07-31) claims 1-42	1-30
Y	WO 01/46185 A (ALEXANDER DAVID L ; HESTER JACKSON B JR (US); UPJOHN CO (US)) 28 June 2001 (2001-06-28) claims 1-37	1-30
	----- -/-- -----	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

16 December 2004

Date of mailing of the international search report

30/12/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Kyriakakou, G

INTERNATIONAL SEARCH REPORT

PCT/IB2004/002983

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with Indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 00/32599 A (HESTER JACKSON B JR ; NIDY ELDON GEORGE (US); PERRICONE SALVATORE CHAR) 8 June 2000 (2000-06-08) claims 1-11	1-30
Y	WO 02/081469 A (SWAIN MICHAEL LINGARD ; ASTRAZENECA UK LTD (GB); BETTS MICHAEL JOHN (G) 17 October 2002 (2002-10-17) claims 1-19	1-30
Y	WO 02/080841 A (SWAIN MICHAEL LINGARD ; ASTRAZENECA UK LTD (GB); BETTS MICHAEL JOHN (G) 17 October 2002 (2002-10-17) claims 1-19	1-30

INTERNATIONAL SEARCH REPORT

PCT/IB2004/002983

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: —
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 27-30 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

PCT/IB2004/002983

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 2004002967	A	08-01-2004	WO 2004002967 A1	08-01-2004
			US 2004077626 A1	22-04-2004
WO 03062231	A	31-07-2003	CA 2473076 A1	31-07-2003
			EP 1467992 A1	20-10-2004
			WO 03062231 A1	31-07-2003
			US 2003232812 A1	18-12-2003
WO 0146185	A	28-06-2001	AU 2050201 A	03-07-2001
			BR 0016605 A	25-02-2003
			CA 2389482 A1	28-06-2001
			CN 1391572 T	15-01-2003
			CZ 20022142 A3	13-11-2002
			EP 1242417 A1	25-09-2002
			HU 0203869 A2	28-07-2003
			JP 2003518117 T	03-06-2003
			NO 20022973 A	20-08-2002
			NZ 519725 A	28-05-2004
			PL 356478 A1	28-06-2004
			SK 7572002 A3	03-12-2002
			WO 0146185 A1	28-06-2001
			US 2001046987 A1	29-11-2001
			ZA 200204166 A	25-08-2003
WO 0032599	A	08-06-2000	WO 0032599 A1	08-06-2000
			AU 764980 B2	04-09-2003
			AU 1705399 A	19-06-2000
			CA 2351062 A1	08-06-2000
			EP 1133493 A1	19-09-2001
			JP 2002531455 T	24-09-2002
			NZ 511963 A	31-10-2003
WO 02081469	A	17-10-2002	WO 02081469 A1	17-10-2002
WO 02080841	A	17-10-2002	WO 02080841 A2	17-10-2002